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Organic dots is a term used to represent materials including graphene quantum dots and carbon quantum
dots because they rely on the presence of other atoms (O, H, and N) for their photoluminescence or
fluorescence properties. They generally have a small size (as low as 2.5 nm), and show good
photostability under prolonged irradiation. The excitation and emission wavelengths of O-dots can be
tailored according to their synthetic procedure, where although their quantum yield is quite low
compared with organic dyes, this is partly compensated by their large absorption coefficients. A wide
range of strategies have been used to modify the surface of O-dots for passivation, improving their
solubility and biocompatibility, and allowing the attachment of targeting moieties and therapeutic
cargos. Hybrid nanostructures based on O-dots have been used for theranostic applications, particularly
for cancer imaging and therapy. This review covers the synthesis, physics, chemistry, and
characterization of O-dots. Their applications cover the prevention of protein fibril formation, and both
controlled and targeted drug and gene delivery. Multifunctional therapeutic and imaging platforms have
been reported, which combine four or more separate modalities, frequently including photothermal or
photodynamic therapy and imaging and drug release.1. Introduction
The complexity of physiopathology of diseases1–3 and the
importance of their early and accurate diagnosis4–7 make new
approaches to overcome these human health issues urgent.
Currently, there is a trend toward not only designing multi-
functional treatment systems for targeting diseases from
various aspects, but also performing the diagnosis with the
same system or track the treatment in real time, which is known
as theranostics.8–12 Moreover, researchers are looking for safer
and more accurate therapies to reduce the side effects and
increase the therapeutic outcome of treatments.13 Due to
various parameters in biological systems, which should be
considered in drug/treatment design for suitable function,of Medical Sciences, Tehran, Iran. E-mail:
tan, Kurdistan, Sanandaj, Iran
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gy, University of Kashan, Kashan, Iran
aculty of Allied Medical Sciences, Iran
an, Iran
ssachusetts General Hospital, Harvard
h Science, University of Johannesburg,
, Iran
the Royal Society of Chemistryproducing a new drug/treatment requires signicant effort.
Accordingly, a system as multifunctional as possible for
controlling or considering a set of parameters is necessary.14
From a diagnostic point of view, the system should be
capable of not only detecting the intended disease with high
sensitivity, but also should distinguish and differentiate the
underlying disease from other possible diseases with similar
characteristics and lab test results, which is known as
specicity.15
Cancer and neurological diseases are some examples of
complex diseases that require specic and sensitive diagnostic
methods as the rst step, and efficient and accurate treatment
in the next step.2,16 Accordingly, theranostics can be a possible
solution for these types of problems. For designing an efficient
theranostic system, researchers have to collect enough knowl-
edge about both physiopathological processes of the diseases
and material sciences.
Theranostics is dened as a combination of imaging and
treatment modalities within a single molecular targeted plat-
form, which can be applied in the next generation of person-
alized medicine.17 In the diagnostic function, the role of
a theranostic agent is to report the presence of a disease, its
location and its extent, and to allow the monitoring of the
response to the therapeutic agent.18 For instance, one applica-
tion is to allow more accurate tumor resection via image-guided
surgery, and to allow post-surgical appraisal of the success of

































































































View Article Onlineimaging of diseased tissue is helpful due to the fact that the
extent of the tumor may have changed aer the initial pre-
surgical imaging and during the course of the resection.19–22
Also, to conrm the complete removal of diseased tissue, post-
surgical imaging is also useful. The second role of theranostics
is to deliver or release therapeutic agents precisely to the tar-
geted location. The agents that are delivered can be chemo-
therapeutic drugs (including, cisplatin, doxorubicin, and
paclitaxel), biologics (such as proteins and antibodies), nucleic
acids for gene therapy (DNA, siRNA, and miRNA), nano-
therapeutic agents, and even therapeutic cells.23–25 These agents
can be fabricated to be responsive to certain stimuli. The
generation of a reactive form of molecular oxygen (singlet
oxygen, 1O2) with the capability to destroy the surrounding cells,
which is triggered by light, is known as photodynamic therapy
(PDT). In contrast, photothermal therapy is based on the
absorption of photons by a chromophore, which creates heat
from optical energy to kill cancer cells.26,27 The third role is the
molecular alteration of a cellular or metabolic process.18 If
particular cell surface receptors are engaged by theranostic
agents, metabolic or cellular pathways may be disrupted, which
can produce a therapeutic effect.28
Theranostic approaches combine multiple techniques into
a single inclusive nanoplatform, oen incorporating molecular
imaging function.29 Molecular imaging can be based on optical
imaging (uorescence/bioluminescence/Raman), computed
tomography (CT), magnetic resonance imaging (MRI), single-
photon emission computed tomography (SPECT), ultrasound
(US), and positron emission tomography (PET).30–32 ThisFig. 1 Four aspects of theranostic agents: (1) cargo delivery (e.g. cells,
different imaging modalities (OI: optical imaging, US: ultrasound imaging
computed tomography, MRI: magnetic resonance imaging, and CT: co
internal or both stimuli and (4) independent therapeutic functions.
2254 | RSC Adv., 2021, 11, 2253–2291technique can be applied for surveying a wide range of biolog-
ical samples, from cells and ex vivo tissue samples, to in vivo
imaging of living organisms and small animals. Moreover, it is
capable of covering a broad range of sizes of organisms, from
sub micrometer-sized viruses and bacteria, to macroscopic
living biological organisms33–35 (Fig. 1).
In theranostic approaches, nanomaterials are oen used for
drug delivery and cancer imaging due to the fact that they allow
the synergistic combination of diagnosis and therapy in a single
nanoplatform.36,37
Among the various groups of nanomaterials, carbon nano-
materials have strong absorption in the infrared (IR) and near
infrared (NIR) region, and thus can be used for photothermal
therapy (PTT) of cancer. Some organic nanomaterials such as
carbon nanotubes and quantum dots show uorescence in the
visible and infrared regions for uorescence imaging.32,38
Additionally, other carbon nanomaterials can convert the
energy from a laser into acoustic signals, which makes them
promising agents for photoacoustic imaging (PAI).39,40 Lastly,
the inherent Raman vibration signals from carbon nano-
materials can also offer a method to track their distribution and
metabolism in vivo.41,42
Among the carbon nanomaterials, carbon-based quantum
dots (CBQDs) including graphene quantum dots (GQDs) and
carbon quantum dots (CQDs) show benecial properties of low
toxicity, environmentally friendly nature, simple and cost
effective synthetic routes, and comparable optical properties to
conventional semiconductor quantum dots and organic
dyes.43–45 Photoluminescent CBQDs are superior to otherproteins, nucleic acids, nanotherapeutics and drugs), (2) imaging via
, PET: positron emission tomography, SPECT: single-photon emission
mputed tomography), (3) stimuli responsiveness to either external or

































































































View Article Onlinequantum dots in terms of solubility, biocompatibility, resis-
tance to photobleaching, chemical inertness, and suitability for
biological applications (one-photon and multiphoton bio-
imaging,46,47 biosensors46,48,49 and biomolecule or drug
delivery48,50,51).2. Definition of organic dots (O-dots)
In the last few years, CBQDs have been utilized in different
biomedical applications, andmany reports have discussed their
synthesis, functionalization, combinations and applica-
tions.52–59 Although graphene quantum dots and carbon
quantum dots have attracted signicant attention, many
researchers are still confused about the differences between
these two sub-groups, and thus their correct and appropriate
use in studies is challenging. GQDs are dened as graphene
sheets with a size in the range of about 3–20 nm, which possess
photoluminescence properties due to their physiochemical
characteristics mostly because of their size,60 while CQDs are
photoluminescence spherical nanoparticles.61 CQDs are also
referred to as carbon dots in some studies. However, there are
some signicant chemical, physical and optical differences
between GQDs and CQDs, which will be discussed below.
As conventional in chemistry and biology, some materials
can be tagged as organic materials, meaning that they are made
of carbon, hydrogen and oxygen as the basic structure of the
material, while they can be natural or synthetic.62 Accordingly,
since GQDs and CQDs are materials with this composition of
elements, we state that they can be categorized as organic
materials and we intend to name them as “organic dots (O-
dots)” or luminescent organic clusters (LOC). This categoriza-
tion may cause some implications including attracting atten-
tion to their chemical and biological properties, expansion of
their biomedical applications and facilitating the design and
fabrication of other types of quantum dot uorescence mate-
rials. Moreover, we hypothesize that due to the emergence ofFig. 2 (a) Formation of type I and type II carbon dots starting from citric a
a nominal unit.62 (b and c) Schematic illustration of the luminescence
absorption spectra of O-dots.62
© 2021 The Author(s). Published by the Royal Society of Chemistrysynthetic biology, the biological synthesis of these materials can
be expected (for example via enzymes), and thus this designa-
tion may provide new ways and approaches toward it. Herein,
different aspects of O-dots are discussed.
A semiconductor quantum dot is a single electronic oscil-
lator, whereas an O-dot is a clustered pack of isolated oscillators
(phosphors).63 Depending on the reaction conditions (temper-
ature, duration of the procedure, and the ratio of precursors),
two types of O-dots can be produced. The rst type is obtained
under mild conditions, e.g. at a moderate temperature. Here,
each dot is comprised of only one type of phosphor, assembled
into a particle mainly due to weak (physical) forces. Upon
further heating, type-I dots can be converted into type-II dots;
however, this step is not reversible. Type II dots are obtained
through deep carbonization of pristine organic substances, and
are more like elemental carbon. In this structure, different
oscillators are linked together via strong bonds (for instance, s-
bonds between carbon atoms). The absorption spectra of type-II
O-dots do not show discrete bands because they consist of
multiple independent oscillators (in contrast to type-I O-dots).
Another distinguishing characteristic of type II O-dots is that
their emission wavelength depends on the excitation wave-
length. However in type-I O-dots, the excitation wavelength just
affects the intensity of the luminescence, and not the wave-
length (color) of the emitted light (Fig. 2).62
This review aims to summarize the recent advancements in
the design and applications of O-dots in theranostics including
bio-imaging, drug delivery, gene delivery and phototherapy. The
organization and scope of this review are shown in Fig. 3.3. Chemical and physical properties
of organic dots
3.1. Chemical properties
The properties of O-dots including CQDs and GQDs depend
mainly on their synthetic routes. Accordingly, the chemicalcid as the carbon precursor. The intermediate “primary fluorophores” is
of O-dots upon excitation, which is related to their size.62 (d) Typical
RSC Adv., 2021, 11, 2253–2291 | 2255

































































































View Article Onlinestructures of O-dots show large variability and chemical char-
acterization is important to gain a better understanding of
particular O-dots (Fig. 4).
For example, GQDs, are composed of a single or multiple
graphene layers with chemical groups attached to the edges,
and they are commonly anisotropic, with lateral dimensions
much larger than their thickness. GQDs are synthesized from
pristine few-layer-thick graphene akes as a precursor.64 They
have a narrow size distribution of 3–8 nm and small sheet-
shaped morphology, as shown by transmission electron
microscopy (TEM) imaging. Due to the presence of a carbon
core, GQDs have a crystalline structure with a lattice spacing of
0.24 nm comparable to the (100) facet of graphite and a honey-
comb lattice with zigzag edges of 7 nm GQDs. This is in contrastFig. 4 Characteristics of organic dots. XPS bonds of CQDs (hydro-
thermal synthesis using 4-aminophenylboronic acid)66 (reproduced
from ref. 66 with permission from the American Chemical Society,
Copyright 2016).
2256 | RSC Adv., 2021, 11, 2253–2291to the spherical CQDs that have been formed using ribonu-
clease A as a bimolecular templating agent under microwave
irradiation, which have an interlayer distance of 0.34 nm,
matching the (002) facet of graphite.65
X-ray diffraction (XRD) provides exact information about the
crystalline structure of O-dots. The strong signal peak at 2q ¼
26.51 shown in the XRD pattern of graphene akes becomes
weaker in GQDs, showing that GQDs are thinner than graphene
akes owing to the additional exfoliation of few-layered gra-
phene. The broad peak positioned at 2q  21.91 (d ¼ 0.41 nm)
may result from the p–p stacking of GQDs. No peaks are
observed in the 2q region of 5–20, demonstrating that the
GQDs are different from GO with fewer oxygen-containing
groups.65 The XRD diffractogram of CQDs formed from 4-ami-
nophenylbenzene displays a broad diffraction peak at around
21.73 with an interlayer spacing of 0.42 nm, which is larger
than that of bulk graphite, indicating the poor crystallization
and amorphous character of the structures.66
Using standard characterization methods such as X-ray
photoelectron spectroscopy (XPS), Fourier transform infrared
(FTIR) spectroscopy, and Raman spectroscopy, the different
surface functionalities on O-dots can be characterized. The
high-resolution C 1s XPS spectrum of CQDs prepared hydro-
thermally from 4-aminophenylboronic acid66 showed bands
corresponding to C–C (283.9 eV), C–C/C–H (285.0 eV), CQO/C–N
(287.3 eV) and O–CQO (290.3 eV). The band at 399.6 eV in the N
1s high-resolution XPS spectrum indicates the presence of
amine groups. The C 1s XPS spectrum of GDQs formed by
cutting pristine graphene akes using an electrochemical redox
reaction in an ionic liquid/water electrolyte under a reverse
potential65 showed peaks related to C–C/C–H (285.0 eV), C–O
(286.1 eV, such as C–OH or C–O–C), C–N (287.2 eV), and O–CQO
(288.5 eV) (Fig. 4a). The N 1s band indicates the presence of two
types of N atoms. The peak at 400.2 eV can be assigned to the N
atom of a pyrrolic structure (imidazolium group) adsorbed or

































































































View Article Onlinemay be incorporated into the graphene layer and take the place
of carbon atoms within the graphene plane.65
The chemical composition of O-dots can be obtained from
Fourier-transform infrared spectroscopy (FTIR). The three
strong bands at around 3425, 1720 and 1645 cm1 shown in the
FTIR spectrum of the GQDs synthesized by an electrochemical
method are associated with the vibrations of the hydroxyl
(–OH), carbonyl (CQO) and graphitic (CQC) groups, respectively.
The band at 1078 cm1 is related to the alkoxy groups (O–C–O)
present in the GQDs. The spectrum reveals that GQDs have
many oxygenated functional groups on their surface. Their FTIR
spectrum is also signicantly different from that of the
precursor graphene akes, with a weak adsorption band at
around 3425 cm1. The FTIR spectrum of CQDs depicts similar
features of distinct strong bands at 3465 cm1 (OH vibration)
and 1618 cm1 (CQO) with additional weak bands attributed to
graphitic CQC (1645 cm1), O–C–O (1078 cm1) and B–O
(1090 cm1), and stretching and deformation vibration modes
of the boroxol bond of the boronic acid moieties.67 The presence
of C–N is demonstrated by the peak at 1400 cm1.
Raman analysis of these organic quantum dots displays the
carbon characteristic D and G bands at around 1350 and
1570 cm1, respectively. The intensity of the D band, which is
related to the presence of sp3 defects, and the G band, related to
the in-plane vibration of sp2 carbon (IG/ID), is a measure of the
disorder in the nanostructure. The Raman spectrum of CQDs
comprises a broad band at 2996 cm1, corresponding to the 2D
graphitic structures, with an ID/IG ratio of z1.24. In the case of
graphene akes used for the formation of GQDs, the weak D and
strong G bands indicate the presence of slightly defective graphene
akes. The increase in the ID/IG ratio (IG/ID ¼ 0.6) of the formed
GQDs suggests the formation of even more defective materials.683.2. Optical properties
O-dots normally show strong optical absorption in the UV
region (260–320 nm) due to the p–p* transition of their C]CFig. 5 Properties of organic dots. Both GQDs and CQDs possess vario
sensitizing nature and high photo-stability.
© 2021 The Author(s). Published by the Royal Society of Chemistrybonds. The shoulder peak located at 270–390 nm is attributed
to the n–p* transition of the C]O bonds.69 The location of the
peak in the spectrum rather than the intensity is more affected
by the preparation route.70–74 Under UV irradiation, different
emission colors have been observed for GQDs, which is related
to the synthetic routes employed. For example GQDs can emit
bright UV,75,76 blue,73,77 green,78,79 yellow,80,81 red79 and near
infra-red82 emissions. The PL emission in O-dots arises from
quantum connement effects, which can be excitation-
dependent and excitation-independent PL83,84 and can be
changed by altering the size of the quantum dots.68 The
quantum yield (QY) is an important factor to evaluate the PL of
O-dots. The QY of naked O-dots is very low, where GQDs have
a higher QY compared to CQDs due to their special layered
structure and crystallinity. However, despite the low QY
commonly found in CQDs, some approaches have been inves-
tigated to improve their QY such as element doping, metal-
enhanced uorescence85,86 and surface passivation/
modication.87
Non-blinking PL and exceptional photostability are the main
benets of O-dots compared to conventional organic or inor-
ganic uorophores. Under continuous excitation with an Xe
lamp, the PL intensity of O-dots is hardly changed for several
hours, while the emission of organic uorophores is changed
within minutes (photobleaching).88 Moreover, in the presence
of solvents or biological systems such as serum, the PL of O-dots
hardly shows any changes.88 Variations in the pH value may
alter the photoluminescence of O-dots, particularly for N-doped
O-dots. The change is more obvious when basic/acidic sites are
involved in the PL emission of the O-dots.89 When the pH value
is increased, the surface charge is converted from positive to
negative. This phenomenon occurs because of the ionization of
amine, carboxyl and hydroxyl groups. Due to the alterations in
the O-dots with a change in pH value, it is possible to create pH-
responsive nanomaterials based on O-dots.90 These O-dots will
be capable of being triggered via pH changes for temporal- and
spatial-controlled cargo release and bio-imaging.91us optical properties including high UV and NIR absorption, photo-

































































































View Article OnlineAlthough the precise mechanism of uorescence in O-dots is
not yet completely understood, two models have been proposed
to account for the PL in CQDs.91 Based on density-functional
theory (DFT) and time-dependent DFT, the PL of GQDs arises
from the quantum connement of the conjugated p electrons
in their sp2 carbon network, which can be governed by the size,
edge conguration, shape, functional groups, heteroatom
doping, and presence of defects.92 The PL process in O-dots
mostly depends on their surface rather than the sp2 clusters
inside their core. In fact, the recombination of electron–hole
pairs creates PL in O-dots.93 This concept has been conrmed by
introducing both electron donors and electron acceptors, which
quench the PL of O-dots.87 Therefore, the optical properties of
O-dots are governed by the interplay between the emissive sites
and non-radiative trap sites on their surface, together with
quantum connement effects.94 CQDs have only a single exci-
tation peak, which triggers the maximum emission, but GQDs
regularly show two separate excitation peaks. The zigzag edges
of GQDs are triplets like carbene, where they possess both s–p
and p–p* transitions, which have an energy difference of
<1.5 eV between the two peaks.80 The different aspects of the
properties of O-dots are illustrated in Fig. 5.3.3. Effects of O-dots on cell viability and cytotoxicity
When nanomaterials are used to deliver exogenous imaging
reporters or therapeutic molecules in living organisms, their in
vivo and in vitro toxicity must be evaluated. In vitro cytotoxicity
testing involves a few different biochemical and morphological
indicators, including cell proliferation, apoptosis, necrosis,Fig. 6 Toxicity of O-dots. The parameters involved in the toxicity of O-d
of impact and together cause damage and alterations in biological syste
malfunctioning.
2258 | RSC Adv., 2021, 11, 2253–2291oxidative stress, and DNA damage. These studies can provide
sufficient information about the biocompatibility of foreign
substances. The evaluation of in vivo toxicity depends on how
foreign molecules or materials are exploited. The physiological
response may vary to a large extent. Therefore, the investigation
of the fate of an externally introduced material involves
absorption, distribution, interaction, metabolism, retention,
and excretion in a living organism. Another difficulty in the in
vivo assessment is the possible toxic effects prompted by the
interactions between the nanomaterial and the living organism.
To investigate this toxicity, monitoring of body weight, blood
chemistry panel, and hematology prole, and histological
analysis are carried out.95,96 For carbon-based quantum dots (O-
dots), both their in vitro and in vivo toxicity have been widely
studied, which are highly dependent on their shape, size, and
surface coating96,97 (Fig. 6).
Zboril and co-workers carried out an inclusive in vitro cyto-
toxicity study on mouse broblasts (NIH/3T3) using 3 types of
CQDs, which were differed in their surface functionalization,
providing overall negative, positive and neutral charges. The
results suggested that the neutral carbon quantum dots had low
toxicity and higher safety up to concentrations of 300 mg mL1.
However, the negatively charged carbon quantum dots caused
morphological changes in the cells, and stimulated prolifera-
tion with higher levels of oxidative stress by interrupting the G2/
M phase of the cell cycle; however, they did not enter the cell
nucleus. In contrast, the positively charged CQDs showed the
greatest toxicity to the cells due to the changes in the G0/G1
phase of the cell cycle, and they could also enter the cell
nucleus, even at low concentrations.98ots are demonstrated above. These parameters define the mechanism
ms. Some of these effects lead to cell death, while others may cause
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 7 (a) Structure of carbon quantum dots coated with HPG. (b) Cell
viability of A549 cells after incubation with CDs or CDs-g-HPG at
different concentrations for 24 h (c) and (d) lysis rate of RBCs incu-
bated with CD-g-HPG and CD respectively101 (figure reproduced from
S. Li, Z. Guo, R. Feng, Y. Zhang, W. Xue and Z. Liu, RSC Adv., 2017, 7,

































































































View Article OnlineThe effect of surface charge on the cytotoxicity and uptake of
CQDs produced from different ratios of citrate and spermidine
as starting materials in human umbilical cord-derived mesen-
chymal stem cells was investigated by Yan et al.99 All the
nanoparticles at concentrations below 50 mg mL1 were non-
toxic. The slightly positively charged CQDs showed a higher
cell uptake efficiency than the negatively charged CQDs. In vivo
assessments were recently done to examine the toxicity of CQDs
derived from glucose, and their surface was stabilized with
ethylenediamine using zebrash as a model.100Fig. 8 Cytotoxicity assays of GQDs. (a) Cell viability results via WST-1 as
Rate of apoptosis in the cells treatedwith GQDs, obtained from flow cytom
(figure has been reproduced from ref. 106 with permission from Elsevie
© 2021 The Author(s). Published by the Royal Society of ChemistryIn another study, the toxicity of CQDs coated with hyper-
branched polyglycerol (HPG) on red blood cells (RBC) was
investigated (Fig. 7). Some CQDs show strong hydrophobic
interaction with the RBC membrane, which can change the
morphology of RBC and cause aggregation. Moreover, the rate
of hemolysis with the use of these components was investi-
gated. The cell viability was signicantly lower than the control
when treated with native CDs at a concentration as low as
0.5 mg mL1. By contrast, the cell viability was not signicantly
different from the control when treated with CDs-g-HPG as high
as 2 mg mL1. Therefore, conjugation with HPG can inhibit the
hydrophobic interaction between the CQDs and RBCs, and
therefore improve the biosafety of CQDs.101
In the study by Wei et al., CQDs were synthesized via
a calcination method using the plant material Gynostemma as
a precursor, which required no toxic reagents or surface
passivation chemicals. The toxicity of different concentrations
of these CQDs (up to 400 mg mL1) was tested in zebra sh,
looking at embryonic development, and the nervous and
circulatory systems. Due to the excellent uorescence stability
and biocompatibility of the CQDs, bio-imaging in zebra sh was
successfully achieved, showing that the CQDs could enter the
zebra sh embryos by the chorion or the mouth. Moreover, the
anti-oxidant effect of the CQDs was investigated both in vitro
and in vivo using oxidative stress induced by H2O2. Biomarkers
were measured including, the level of reactive oxygen species
(ROS) content and malondialdehyde (MDA). The oxidative
stress markers were lower aer treatment with CQDs compared
to the control groups, showing that the uorescent CQDs could
reduce the oxidative damage by controlling the generation of
ROS. Furthermore, the presence of the CQDs promoted the
mRNA expression of related genes, which encode antioxidantsay under 24 h of exposure with GQDs at different concentrations. (b)
etry with annexin-V-FITC/PI staining. (c) Quadrant analysis of the flow
r, Copyright 2019).
RSC Adv., 2021, 11, 2253–2291 | 2259
Fig. 9 Toxicity assays of graphene quantum dots. (a) WST-1 assay, (b)
cell apoptosis and necrosis results, (c) LDH assay, (d) ROS generation
assay, (e) weight of surviving mice with no difference compared with
the control group, (f) effect of PEG-GQD and PEG-GO injection seven
times into the mice and their living status, which is lower in GO. (g)
Weight indexes of the main organs collected on day 40 from the mice
injected with PEG-GO and PEG-GQDs, which indicates abnormality in
the PEG-GO group. All these assays together demonstrate the low
toxicity of GQDs (Figure has been reproduced from ref. 109 with

































































































View Article Onlineproteins to prevent oxidative damage in zebra sh. Therefore,
uorescent CQDs can be a potential candidate for the treatment
of some diseases associated with oxidative damage.102
Possible toxicity to mitochondria and metabolic distur-
bances are other important issues that must be addressed. The
results from previous studies indicated that the mitochondrial
toxicity of carbon quantum dots, which ultimately leads to cell
death, was very low at concentrations of up to 500 mg mL1 over
a period of 24 h, and the cell viability was higher than 82%.
Nevertheless, aer increasing the concentration to 1 mg mL1
for longer than 24 h, there a cell death rate of about 40% was
observed. Thus, the dose-dependent toxicity of O-dots towards
mitochondria can be used to deliver drugs to cells at low doses
and kill cancer cells at high doses.103
It is also important to assess the potential ability of GQDs to
produce DNA damage since there is a close correlation between
DNA damage and carcinogenesis. In a study reported by Wang
et al., the genotoxicity of GQDs towards NIH- 3 T3 cells was
investigated by ow cytometry analysis for DNA damage-related
protein activation, while the GQD-induced ROS generation was
studied as a potential explanation for DNA damage. The cellular
uptake of GQDs and the cell death and proliferation of NIH-3T3
cells treated with GQDs were also studied to assess the cyto-
toxicity of GQDs.104 An analysis of GQD-mediated photodynamic
cytotoxicity was performed by Markovic et al., demonstrating
that photodynamic activation could induce oxidative stress and
generate in vitro cytotoxicity, and subsequent activation of both
apoptosis and autophagy programmed cell death pathways.105
However, studies on human breast cancer cells indicated that
GQDs are non-toxic materials since they rapidly enter the
cytoplasm but do not interfere with cell proliferation.
In another study using lung carcinoma A549 cells as amodel,
the cytotoxicity of three types of GQDs, including cGQDs
(COOH-GQDs), hGQDs (OH-GQDs), and aGQDs (NH2-GQDs)
was investigated. The results showed that hGQDs were the most
toxic since signicant cell death was induced at a concentration
of 100 mg mL1, as determined by the WST-1 assay as well as
annexin-V-FITC/PI apoptosis analysis, whereas cGQDs and
aGQDs were non-toxic in the tested concentration range
(Fig. 8).106
The toxicity of GQDs to HeLa cells was tested using the CCK-
8 assay, showing that the cell viability decreased with an
increase in GQD concentration. More than 90% cell viability
was observed at concentrations ranging from 21.5 to 50 mgmL1
and nearly 80% cell viability was obtained at the highest
concentration of 200 mg mL1, which proves that a low
concentration GQDs is biocompatible with low toxicity to HeLa
cells. Furthermore, the lactate dehydrogenase (LDH) levels
indicated the integrity of the cell membrane, conrming the low
cytotoxicity of GQDs.107 In this work, the HeLa cells were
exposed to different concentrations of GQDs for 24 h and then
the LDH release was measured. The LDH release Hela cells
incubated with various concentrations of GQDs for 24 h indi-
cates that the LDH release levels were slightly higher than the
control group at a low concentration of GQDs, suggesting that
only a small fraction of the HeLa cell membrane was compro-
mised by GQDs. However, compared to the control group, the2260 | RSC Adv., 2021, 11, 2253–2291LDH release level increased to about 50% with a high concen-
tration of GQDs, suggesting that GQDs could enter the cells
through endocytosis108 and cause corresponding membrane
damage. The ROS assay is another effective technique to detect
the oxidative stress levels in cells. Furthermore, the intracellular
ROS level was low with GQDs at concentrations in the range of
0 to 50 mg mL1, while the ROS level signicantly increased at
a GQD concentration of 200 mg mL1. All these results suggest
that a low concentration of GQDs displays relatively low cyto-
toxicity, while a high concentration (200 mg mL1) shows more
cytotoxicity.
Chong et al. reported a detailed and systematic study on the
in vivo toxicity of GQDs.109 To simulate the drug administration
in humans, 48 female mice were randomly divided into four
groups, including a control group and GQDs functionalized
with polyethylene glycol (PEG-GQDs) administered intraperito-
neally (i.p.), PEG-GQDs administered intravenously (i.v.) and
PEG-GO administered intraperitoneally (i.p.). There was no
obvious difference between the various administration routes of
PEG-GQDs, and all the mice injected with PEG-GQDs survived

































































































View Article Onlinemice treated with PEG-GO died, while the remainder of the GO
group displayed no signicant loss in body weight (Fig. 9g). In
addition, the weights (Fig. 9g) of the liver and spleen from the
mice injected with PEG-GO were larger than that in the other
groups, suggesting chronic damage to the liver and spleen
caused by PEG-GO. In addition, dark spots were observed in the
liver and spleen from the mice injected with PEG-GO, while
nothing was found in the organs from mice injected with PEG-
GQDs. The other toxicity assay results are shown in Fig. 9. All
the above results showed that the PEG-GQDs possessed lower
cytotoxicity than PEG-GO due to the size-effect of graphene
materials.
In a summary, it can be said that toxicity is a state of a bio-
logical system malfunctioning aer the administration of
materials to the body under certain conditions. The interaction
of these materials with different components of biological
systems is a reason for this malfunctioning, which is related to
the characteristics of materials. In the case of O-dots, their
electrical charge, functional groups, modication, morphology,
hydrophobicity and concentration dene the quality of the
interaction between them and biological systems. Carbon-
based materials are active materials, and this property allows
the possibility of their efficient functionalization and modi-
cation, but also allows them to take part in unwanted reactions
with biological components. Thus, by manipulating these
parameters, it will be possible to come up with a structure that
possess a balance between maximum function and minimum
toxicity. As it mentioned previously, biological systems are
complex and their different parts react differently; therefore,
more studies on the interaction of different levels of biological
systems (organelles, cells, tissues and organs) of different types
are necessary.Fig. 10 Synthetic approaches for O-dots. (a) Top-down methods inclu
methods with mentioned resources. (b) Bottom-top methods including
mentioned carbon precursors.
© 2021 The Author(s). Published by the Royal Society of Chemistry4. Synthesis of O-dots
A variety of methods have been used for the preparation of O-
dots (CQDs and GQDs) (Fig. 10). In this section, we summa-
rize the different approaches for the production of O-dots.
Regardless of the specic carbon nanostructure, the synthetic
approaches can be categorized into two main categories, i.e. the
top-down and bottom-up methods.
Top-down methods are based on the progressive break down
of larger carbon structures (e.g., graphite powder, carbon rods,
carbon nanotubes, carbon black and even candle soot)110 by
various methods including, laser ablation,111 hydrothermal,112
electrochemical oxidation113,114 and arc discharge115 (Fig. 8a).
This method offers some advantages such as abundant raw
materials for the fabrication of O-dots, large-scale production,
and simple operation. The obtained O-dots possess a highly
crystalline nature and good aqueous dispersibility. However,
these nanomaterials commonly demonstrate a predominant
sp2 hybridized carbon structure, and therefore oen lack an
efficient electron band gap to provide uorescence. Therefore,
the size and surface chemistry should be modied via oxidizing
agents such as concentrated acids (HNO3 and H2SO4/HNO3
mixture). In this process, the bulk carbon materials are reduced
into smaller fragments, while the surface is altered with oxygen-
containing groups. This two-step route has become well-
established for the formation of GQDs. In the rst step,
graphite is converted into graphene oxide (GO) sheets using the
Hummers' method, while the second step involves cutting the
GO into GQDs using various methods.59
The bottom-up approach employs certain molecular
precursors that can form O-dots aer dehydration and
carbonization procedures. In general, the best precursorsding laser ablation, hydrothermal, arc discharge and electrochemical
ultrasonic, microwave pyrolysis and hydrothermal methods with the

































































































View Article Onlinepossess –OH, –COOH, –CQO, and NH2 groups, which can be
dehydrated at higher temperatures. There are numerous
approaches to perform the dehydration and carbonization
processes, including hydrothermal,66 microwave-hydro-
thermal,116 plasma-hydrothermal approaches117 (Fig. 10b).
These methods offer exciting opportunities to control the
molecular size, and shape and ne-tune the physicochemical
properties of O-dots.
4.1. Top-down approaches
The main idea of top-down methods is based on the fabrication
of nanostructures from bulk materials. As will be discussed
further in detail, in the top-down methods, bulk materials are
broken down into their primary building blocks by applying an
external source of energy and then become reconstructed into
nanostructures with certain morphologies and atom congu-
rations (Fig. 10a). An external source of energy, bulk carbon
precursors and a suitable medium are the requirements for
these methods, and based on these parameters, it is possible to
invent new top-down fabrication methods (Fig. 11).
4.1.1. Electrochemical synthesis. Electrochemical etching
of various carbon-based electrodes is a practicable low-cost
procedure for the formation of O-dots (Fig. 11a). In this
method, carbon electrodes such as graphite-rod electrodes are
electrochemically broken down into CQDs and GQDs. One of
the rst electrochemical syntheses of GQDs was reported by
Zhou et al.,118 in which GQDs were prepared during electro-
chemical cycling of MWCNTs as carbon precursors in the
presence of tetra-n-butyl ammonium ions (Fig. 12). The oxida-
tion of graphitic electrodes at +3.0 V was proposed by Zhao
et al.119 to prepare CQDs with emission wavelengths at 445 nm
and 510 nm.
Alkali-assisted electrochemical etching allowed the prepa-
ration of CQDs with a controlled size.120 The electrochemical
synthesis of photoluminescent CQDs from glycine underFig. 11 Major top-down synthetic methods. (a) Electrochemical oxidatio
(1) One electrode is made of carbon, while the other one is platinum. The
In the second type of cell, both electrodes are made of platinum, and t
method. Laser irradiation is used as a source of energy to break down grap
discharge between two electrodes in a gas-filled tube cut out of carbo
forming carbon structures.
2262 | RSC Adv., 2021, 11, 2253–2291alkaline circumstances was recently reported by Wang et al.114
The application of +10 V between two Pt electrodes led to the
oxidation of glycine (Fig. 9a) and resulted in the formation of
ammonium ions, which further reacted with non-oxidized
glycine through an amidation reaction. The ions produced
allowed electro-polymerization, carbonization and passivation
to form highly uorescent CQDs with an average size of 2.4 
0.4 nm and a crystalline structure.
In another study, water-soluble red uorescent GQDs with
a uniform size of 3 nm and red emission were successfully
prepared without any chemical modication via the electro-
chemical exfoliation of graphite in a K2S2O8 solution. The RF-
GQDs were isolated sp2 domains with a diameter of 3 nm
generated by the very active SO4
 radicals produced from
S2O8
2 as electrochemical “scissors” to precisely cut the gra-
phene sheets into small intact sp2 structures.70
4.1.2. Arc discharge method. Arc discharge is the electrical
breakdown of a gas to form plasma, which has been widely
applied for the preparation of carbon nanomaterials.121 The
chamber of this system contains two electrodes, i.e. the anode,
which contains powdered carbon precursors, and the cathode,
which is frequently a pure graphite rod. Aer lling the
chamber with a gas or a liquid and applying a power supply
(AC or DC), the electrodes are brought into contact to generate
an arc. During arc discharge, a large amount of heat is
produced, resulting in sublimation of the carbon precursors in
the anode, which then move towards the cathode where they
are deposited in the form of nanostructures (Fig. 11c). Aer
oxidation of the crude materials (soot) in nitric acid, alkaline
extraction and purication via gel electrophoresis, hydrophilic
uorescent CQDs are formed.122 The main weakness of this
approach is the existence of different sized and non-uniform
carbon nanostructures in the nal mixture, which are oen
hard to separate.n is performed in electrolytic cells, which can be divided into two types.
carbon electrode in this electrolytic cell acts as a carbon precursor. (2)
he carbon precursors are dispersed in the medium. (b) Laser ablation
hite into carbon atoms and formGQDs or CQDs in themedium. (c) Arc
n atoms from powdered carbon. Carbon atoms drift into the cathode
© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 12 Electrochemical preparation of GQD from MWCNT. Electrochemical oxidation of MWCNTs and subsequent electrochemical reduction

































































































View Article Online4.1.3. Laser ablation. A rapid way to synthesize CQDs is the
laser ablation of carbon-based bulk materials (Fig. 11b).
Although, there are several interesting reports using laser
ablation for the synthesis of CQDs, the large-scale synthesis of
CQDs via laser ablation is rather difficult due to the narrow zone
of target erosion and the low synthetic yields. Surface passiv-
ation can be achieved by further reuxing in HNO3 for 12 h and
post-modication with polyethylene glycol (PEG) groups. The
laser ablation of activated carbon (4% ash) in a water/ethanol
solution (5 : 2) was reported by Yogesh et al., which led to
CQDs 4 nm in size.123 A one-step process based on the irradia-
tion of a graphite target using a 532 nm second harmonic beam
of an Nd:YAG laser in H2O/ethanol or diethylenetriamine penta
acetic acid solution for the formation of 3 nm-sized CQDs was
described by Tarasenka et al.124 The synthesized particles
exhibited strong photoluminescence in the visible region. The
laser ablation of a solid carbonmaterial in a liquid environment
with laser pulses of 1064, 532 and 355 nm at different irradia-
tion times was recently investigated.111 A wide size distribution
of the CQDs was observed for the 1064 nm laser due to the
deeper penetration of the laser into the dielectric during the
ablation process, and therefore this wavelength is less suitable
for the formation of size-controlled CQDs.
4.2. Bottom-up approaches
Since GQDs and CQDs are formed from carbon atoms organized
in specic congurations, some carbon-based precursors can
be used for the synthesis of these nanomaterials (Fig. 10b).
Accordingly, these precursors act as carbon backbones, which
can join together in a specic manner to form GQDs or CQDs
under specic synthetic condition. For this purpose, a carbon
precursor, a source of energy and a suitable medium are
required. Specically, the building blocks of GQDs and CQDs in
the bottom-top methods are materials with small carbon chains
that can merge under irradiation of an energy source and form
honeycomb sheets of carbons or spherical carbon nano-
particles. The synthetic conditions can explain the difference© 2021 The Author(s). Published by the Royal Society of Chemistrybetween the formation of GQDs and CQDs since different bonds
will be formed under different conditions.
4.2.1. Pyrolysis or carbonization of organic precursors. The
pyrolysis of small organic molecules involves three steps of
condensation, nucleation, and subsequent formation of larger
O-dots. These steps are carried out by heating small organic
molecules above their melting point. The precursors of this
method can be organic salts (e.g., octadecyl ammonium citrate
or diethylene glycol ammonium citrate125), coffee grounds,126
glycerol,127 L-glutamic acid,128 ascorbic acid,90 citric acid,129,130
and ethylenediaminetetraacetic acid disodium salt (EDTA-
2Na).131 Besides simple combustion, plasma132,133 and micro-
wave134 heating methods have been also explored. These
methods are simple, economical, accessible, and allow the
natural inclusion of heteroatoms, which are derived from the
precursors.135 John and coworkers utilized a simple and cost-
effective technique in which the pyrolysis of cotton was
applied as a green method for the preparation of CQDs. Low
cytotoxicity, good photostability and broad blue and green
uorescence emissions were the advantages of the CQDs
produced by this procedure.88
4.2.2. Microwave-assisted synthesis. Microwave-assisted
synthesis is an effective and time-saving approach for synthe-
sizing O-dots. The in situ and transient heating procedure,
increased production yield and improved chemical and physical
properties are some of advantages of this method.136,137 The
microwave pyrolysis approach was described by Zhu et al. for
the rst time.138 In their work, CQDs were produced by mixing
PEG200 with a saccharide component such as glucose or fruc-
tose in distilled water, in a 500 Wmicrowave oven for 2–10 min.
Subsequently, the color of the solution changed from colorless
to dark brown, showing the formation of CQDs. In another
approach, CQDs were synthesized using poly(ethylenimine)
(PEI) and glutaraldehyde as precursors via a microwave-assisted
green synthetic procedure. Changing the molar ratio of glutar-
aldehyde to PEI led to the formation of different emission colors

































































































View Article Online5. Surface engineering of O-dots
For better interacting with biological systems, modication of
O-dots with different molecules and structures including
biomolecules is necessary. Moreover, surface modication can
alter the surface characteristics of a material to make it more
suitable for a particular application.140,141 For this purpose, the
addition of functional groups on O-dots will facilitate this
process. Also, functionalization may change some of their
physical and chemical characteristics.142
The surface functional groups available on the surface of O-
dots depend on the type of precursors and the reaction condi-
tions.59 The functional groups present on the surface of O-dots
include –OH and –COOH depending on the degree of oxida-
tion. These groups readily form hydrogen bonds with water
molecules, and their presence leads to reasonable solubility in
water. Furthermore, these groups play a vital role in the
enhancement of the PL efficiency. Therefore, alterations in the
degree of oxidation can affect the optical properties of the O-dots.
The QY of GQDs increases with a reduction in the oxygenation
rate of GQDs, while the emission wavelength will be shied
towards longer wavelengths (red-shi) by their oxidation.92,143–145
In addition to these benecial functional groups, additional
functionalization with other materials such as polyethylene
glycol (PEG) is necessary to improve the biocompatibility and also
the QY of organic dots. The need for surface passivation offers
some constraints in the synthetic procedure, which increases the
overall particle size, resulting in a deleterious effects on the
applications in of O-dots in different elds. PEG molecules,
which are applied as surface passivation agents, can increase the
inherent uorescence emission.87,135 In addition to PEG, other
small molecules such as ethylene diamine, octadecylamine, and
2-(2-aminoethoxy)-ethanol have been covalently linked to the
surface of O-dots via an amide bond. Surface passivation leads to
hydrophilicity and hydrophobicity in organic dots based on the
nature of the functional groups.125,146 Furthermore, the additionFig. 13 GQD functionalization and modification with other elements. Fu
increase in solubility, better photoluminescence and catalytic properties
2264 | RSC Adv., 2021, 11, 2253–2291of heteroatoms (especially nitrogen) can improve the PL and QY
of carbon dots. N-doping of GQDs increases their QY and
produces a blue-shied emission due to the strong electron-
withdrawing ability of the N atoms within the conjugated C
plane.80,92,130,147 To add catalytic functions to organic dots or to
improve their PL properties, other elements (e.g., Si,148 P,149 S150,151
and B108) have also been doped into CQDs and GQDs. S and N co-
doped CQDs and GQDs can have a QY value as high as 73% and
71%, respectively.108,150 Thus far, different functional groups such
as amine, carboxyl, quaternary ammonium and alkoxysilane have
been coated onto the surface of O-dots (Fig. 13). The most
common groups detected on the O-dot surface are amine and
carboxyl, which allow the conjugation of organic, polymeric,
inorganic or biological moieties.152–154 Herein, some approaches
for surface modication will be discussed.5.1. Amine capped CDs
Branched poly(ethylenimine) (BPEI), 2,20-(ethylene-dioxy)bis
(ethylamine) (EDBEA), 4,7,10-trioxa-1,13-tridecanediamine
(TTDDA), poly(ethylene glycol)diamine (PEG1500N), ethyl-
enediamine (EDA), polyenepolyamine (PEPA), tetraethylene-
pentamine (TEPA), urea and chitosan have been used to coat the
surface of O-dots due to their amine groups. The synthesis of
these types of coated O-dots is carried out using different
approaches including microwave irradiation, hydrothermal
carbonization, and pyrolysis, which convert carboxyl groups to
amine groups.
5.1.1. Microwave irradiation. This simple and rapid
approach has been utilized for the preparation of amine-capped
CDs. Citric acid (CA) and ethylenediamine (EDA) are custom-
arily used to fabricate the carbon core with amine groups on the
surface. A colorless solution of CA and EDA is combined under
vigorous stirring. Next, the clear transparent solution is placed
in a microwave oven and heated for a certain time.155 Aer
dissolution, sonication and dialysis, moderately pure amino-nctional groups and heteroatoms add different properties to GQDs (i.e.
).

































































































View Article Onlinecapped CQDs are produced.153,154,156 Another material used for
the preparation of amine-capped CQDs is 2,20-(ethylenedioxy)
bis(ethylamine) EDBEA. When the color of the transparent
solution changes from a colorless liquid to a brown solid
precipitate, the amine-coated C-dots are ready to be
collected.157,158 Multicolor carbon dots produced from D-fructose
and NH4HCO3, called F-CQDs, were synthesized via a time and
energy-saving microwave-assisted approach. Manganese oxide
carbon quantum dots were synthesized via a microwave
approach. These materials were used for bioimaging and cell
tracking via uorescence microscopy for up to 12 cell genera-
tions with only nominal cytotoxicity.88
5.1.2. Hydrothermal method. The hydrothermal approach
is an eco-friendly method and has attracted signicant atten-
tion. CQDs were produced by mixing citric acid and EDA at
200 C for 5 h. As a result of citric acid and EDA condensation,
polymer-like CQDs were formed. Subsequently, the polymer was
carbonized to yield amino-coated CQDs.46,159,160 Chitosan is
another material used to synthesize amine-capped O-dots due
to its abundant amino/oxygen groups.161 The hydrothermal
carbonization of chitosan was carried out in a 2% aqueous
solution of acetic acid in a Teon-lined stainless steel autoclave
at 180 C for 12 h. Aer centrifugation and removing the black
precipitate, amine-capped O-dots were obtained.162,163 Mintz
and his team reported the preparation of tryptophan quantum
dots, which could easily cross the blood–brain barrier via the
LAT1 transporter, which made them an appropriate candidate
for drug delivery and imaging of brain tissue. Two other
nitrogen dopants, i.e. urea and 1,2-ethylenediamine, were also
used in this approach. The carbon dots possessed an excitation
wavelength-dependent emission, low toxicity, and were
observed inside the central nervous system of zebra sh (Danio
rerio). This observation conrmed that tryptophan quantum
dots can cross the blood–brain barrier.88
5.1.3. Pyrolysis. In this method, materials such as poly-
enepolyamine (PEPA) are used as a primary amine source to
prepare O-dots coated with amine groups.152 Using this
approach, a mixture of citric acid and PEPA was heated to
170 C in an oil bath and kept for 0.5–2 h. Aer cooling the
mixture to room temperature and adding acetone, the amine-
capped CQDS precipitated and the product was collected by
centrifugation. The nal solid amine-capped CQDs were ob-
tained by dialysis and lyophilization. Another route for the
synthesis of amino-coated CQDs was reported by Liu et al.164
They utilized tetraethylenepentamine (TEPA) as an amine donor
to synthesize amine-capped CQDs under nitrogen protection in
a three-neck ask. Once TEPA was heated to 240 C, anhydrous
citric acid was rapidly added to the solution under vigorous
stirring. The pyrolysis reaction occurred over 3 min at 240 C.
Aer dialysis and vacuum drying, the product was nally
obtained.
5.1.4. Converting surface coating from carboxyl to amino
groups. Amine-coated O-dots can be synthesized by converting
the carboxyl groups on their surface to amino groups via a two-
step process. Initially, glucose in 2% acetic acid solution was
carbonized via the hydrothermal method at 180 C for 6 h,
yielding the carboxyl-coated O-dots. To alter the surface coating© 2021 The Author(s). Published by the Royal Society of Chemistryaer dialysis, PEG1500N was added to the carboxyl-coated O-dot
solution and the mixture was heated to 120 C for 12 h. Aer
dialysis, a comparatively pure solution of amine-coated O-dots
was obtained.165
5.2. Carboxyl group-coated O-dots
Several approaches have been reported to produce carboxyl
group (carboxylate)-coated C-dots, including pyrolysis, micro-
wave irradiation, and chemical oxidation.166 Accordingly, O-dots
coated with carboxyl groups were prepared using CA with
pyrolysis at 180 C for 150min under normal air.167 This method
was modied by Reisner et al.168 who carried out the reaction for
40 min. In this approach, further purication was not necessary
because no residual citric acid was detected in the sample. A
similar material was obtained using amicrowave oven, in which
glucose and poly(acrylatesodium) (PAAS) were dissolved in
water and then heated for 4 min. Aer purication, carboxyl-
capped C-dots were obtained.169 Chemical oxidation is
another approach used for the preparation of O-dots capped
with carboxyl groups. In this approach, different carbon sour-
ces, such as activated carbon or petroleum coke are employed.
These materials are chemically oxidized in concentrated HNO3
or a mixture of concentrated H2SO4 and HNO3 at a temperature
higher than 100 C for more than 12 h.170,171 Aer centrifuga-
tion, the supernatant is removed and neutralized by NaOH.
Then, the carboxylate-capped O-dot solution can be collected by
dialysis. Callan et al.172 changed the surface coating of O-dots
from amine to carboxyl groups via a reaction occurring
between the amine groups and succinic anhydride at a basic
pH. The synthesis procedure was based on two steps. Firstly, the
amine-capped O-dots were prepared using carbon nanopowder
reuxed in nitric acid for 12 h. Then, the dried oxidized carbon
nanoparticles were reuxed in neat SOCl2 for 6 h. Finally, the
product was reacted with bis-3-aminopropyl terminated poly(-
ethylene glycol), forming amino-capped O-dots. In the second
step, the reaction between amine-capped C-dots and succinic
anhydride led to the formation of carboxyl-capped dots. Suc-
cinic anhydride reacted with the amine capped O-dots in
CH2Cl2 solution containing Et3N, and the reaction was
continued for 15 h under argon at ambient temperature. Then,
the mixture was neutralized with aqueous HCl, and the carboxyl
coated O-dots were extracted with CHCl3. Aer dehydration of
the organic phase over Na2SO4, the solvent was removed under
reduced pressure, and dark yellow carboxyl terminated O-dots
were nally obtained.
5.3. Surface coating with quaternary ammonium
Several studies have reported the preparation of O-dots with
a cationic surface coating,173–178 which are generally synthesized
in three steps as follows. In the rst step, a concentrated acidic
solution of betaine hydrochloride was neutralized by the addi-
tion of tris(hydroxy methyl)-amino methane (Tris) at a molar
ratio of 1 : 1. Aer this step, the water-soluble organic salts were
partially removed from the solution with isopropanol. A dry
viscous white precursor was produced, and subjected to pyrol-

































































































View Article Onlinebeyond this point, it may lead to the degradation of betaine, and
thus 250 C was adequate for the carbonization of Tris. The
resultant product was extracted with water and precipitated
from the colloid using acetone. Aer washing and drying, the
surface quaternized O-dots were obtained as a dark brown
powder.5.4. Alkoxysilane coating
Amino-terminated alkoxy silanes including N-(b-aminoethyl)-g-
aminopropyl methyl dimethoxy silane (AEAPMS)179,180 and [3-(2-
aminoethylamino)propyl]trimethoxy silane (AEATMS)158,181 have
been used. These compounds were heated to 230–240 C, and
then anhydrous citric acid was added quickly under vigorous
stirring. In the course of pyrolysis, citric acid was rapidly
decomposed and carbonized in an oxygen-free environment,
which led to the formation of carbon nanoparticles with
residual carboxylic acid groups. Amide bonds were obtained via
reaction of the terminal NH2 on the alkoxy silanes with the
residual carboxylic acid groups. The carbon nanoparticles were
attached to the alkoxy silane via amide bonds. The products
were puried by precipitation with petroleum ether or a mixture
of toluene/hexane repeated three times.6. O-dots and biological materials
As discussed previously, the reactive groups present in the
surface coating of O-dots can be modied according to the
requirements. Numerous organic, polymeric, inorganic orFig. 14 Interaction of O-dots with biological components. (a) O-dots pre
with each other. (b) O-dots cause disruption in cellular membrane in
membranes, leading to cell lysis and changes in photoluminescence. (c
conformational changes in them.
2266 | RSC Adv., 2021, 11, 2253–2291biological materials with specic functions can be attached on
the surface of O-dots. Moieties can be attached to O-dots via
several different interactions, including covalent bonds, elec-
trostatic interactions and hydrogen bonds for specic
applications.6.1. Interactions in functionalized O-dots
Callan et al.172 reported the preparation of a CQD-NO photo-
releasable nanohybrid system for the two-photon photo-
therapy of hypoxic tumors. This nanohybrid was produced via
an amide bond formation reaction using ethyl(-
dimethylaminopropyl)carbodiimide (EDC) plus N-hydrox-
ysuccinimide (NHS). The carboxylic acid-coated CQDs were
activated by EDC/NHS in PBS at room temperature for 20 min.
Then a DMSO solution of the amine-terminated nitroaniline
derivative NO photodonor was reacted with the activated
carboxyl groups for 4 h at room temperature. The desired
product was then obtained aer purication. Sulfur-doped
CQDs can be linked to dopamine via electrostatic interaction
or hydrogen bond formation. The binding relies on the key role
of NH2 groups and the aromatic ring, which occurs in plasma.
This binding can be very useful for the detection of any
abnormal dopamine that may be present in neurological
disorders such as schizophrenia, Parkinson's disease and
Huntington's disease.182 In another study, Liu et al.155 reported
a multifunctional platform for serum-resistant gene delivery
and bioimaging based on O-dots modied with a poly cationic-
b-poly-zwitterion copolymer using an atom transfer radicalvent protein fibrillation by preventing the interaction of protein subunits
tegrity, enter cells via endocytosis and cause chemical variations in
) O-dots attach to nucleic acids via electrostatic interaction and make

































































































View Article Onlinepolymerization (ATRP) reaction. In this method, the PDMA/O-
dots were prepared according to the following procedure.
Bromine-functionalized CQDs, 2-(dimethylamino)-ethyl meth-
acrylate (DMAEMA), N,N,N0,N00,N00-pentamethyl-
diethylenetriamine (PMDETA), and NaCl were added to
a degassed ethanol suspension of CuCl2 under N2 protection,
and the reaction was continued for 3 h at room temperature. An
aqueous solution of MPDSAH was then injected into the
mixture and the reaction was allowed to proceed at room
temperature for 24 h. The solution was dialyzed against
deionized water for 7 days to completely remove the impurities,
and was subsequently freeze dried. Anhydrous polymer-
modied CQDs (PDMA-PMPD/CQDs) were eventually obtained.
Functional groups can also be attached to the surface of O-
dots via hydrogen bonds. For instance, Ouyang et al. devel-
oped a novel turn-on uorescence probe for the targeted
imaging of cancer cells via the hydrogen bond interactions
between folic acid (FA) and carboxyl-coated CQDs. The probe
was synthesized by mixing FA and CQDs in an aqueous solu-
tion, which was dialyzed three times against pH 7.4 PBS buffer
for 2 h.169 In another study, bi-functional protein nano ber
(PNF)–GQD nano-hybrids based on non-covalent interactions
(p–p and electrostatic) between motif-designed PNFs and
uorescent GQDs were synthesized. Because these PNF–GQD
nano-hybrids possessed both a recognition moiety (RGD
peptide) and a uorescent imaging probe (GQD), they could
simultaneously target and image tumor cells.1836.2. Interactions of O-dots with biomolecules
6.2.1. O-dot interaction with protein brils. The formation
of peptide or protein brils within the extracellular space of
tissue (Fig. 14a) is believed to play a signicant role in the
development of serious diseases such as Alzheimer's disease,
Parkinson's disease and type-II diabetes.184,185 The formed
mature protein brils are known to be cytotoxic and can
provoke the death of affected cells.186 Therefore one preventa-
tive or therapeutic strategy for diseases associated with peptide
or protein brillation is to inhibit or delay the brillation
process. Various components including organic molecules,187
functional polymers,188,189 QDs,190,191 and carbon-based nano-
materials192 have been explored to inhibit peptide or protein
brillation. The possible application of O-dots for the inhibition
of protein brillation was recently reported. Specically, one
new type of CQDs was prepared by Li et al.,193 who investigated
their effect on the brillation of human insulin. In this study,
the formation of insulin brils was signicantly delayed when
CQDs were added in a dose-dependent manner. No insulin
brils were observed aer incubation at 65 C for 5 days (i.e. 120
h) when a large concentration of CQDs (40 mg mL1) was
present. Moreover, when the CQDs were covalently attached to
other proteins (such as transferrin, human serum albumin,
chicken ovalbumin, and hemoglobin), no protein brillation or
conformational alteration was detected, even aer 48 h at
ambient temperature.194 Mechanistically, the inhibitory effect of
CQDs on insulin brillation was most efficient when added in
the early stages, showing that the inhibitory effect was possibly© 2021 The Author(s). Published by the Royal Society of Chemistrydue to the interactions between the CQDs and insulin species
(monomers or oligomers) before a critical nucleation concen-
tration was reached.195 The inhibitory effects of CQDs on human
islet amyloid polypeptide (hIAPP) and amyloid peptide b 33-42
(a key fragment of Ab 42) have also been reported.196 Interest-
ingly, O-dots prepared by different synthetic routes can exhibit
different inhibitory effects. In a recent study, hIAPP brillation
was inhibited by CQDs produced from organic material
precursors, while the CQDs prepared from graphene oxide (GO)
were surprisingly shown to stimulate the formation of brils.196
The different effects on amyloid brillation were ascribed to the
differences in the structure and surface properties of these
CQDs. Architecturally, the CQDs obtained from organic
precursors tend to be spherical particles with plentiful nitrogen/
oxygen-based functional groups on their surface. The strong
interaction among these hydrogen-bond donating groups and
the backbone groups of the peptide was proposed to prevent
hIAPP from ripening into brils due to the electrostatic repul-
sion of the charged particles against each other. By contrast, for
CQDs synthesized from GO sheets, hydrogen bonds between
the backbone of the peptide and the CQDs were less likely to
occur due to the steric effects from the large hydrophobic edges
on GO. Furthermore, these CQDs also inherited the layered
structure from GO, which could strongly absorb peptides via
their aromatic and hydrophobic residues. The strong p–p and
hydrophobic interactions between the peptide chains and the
CQDs increased the local peptide concentration, and destabi-
lized the folded state, which promoted the aggregation of the
peptides.197
Fluorinated graphene quantum dots (F-GQDs) are a new type
of carbon nanomaterials with unique physicochemical proper-
ties due to their highly electronegative uorine atoms. Yousaf
et al. prepared highly uorescent and water-dispersible F-GQDs
using a microwave-assisted hydrothermal method, and inves-
tigated their inhibitory effect on the aggregation and cytotox-
icity of hIAPP in vitro. The efficient inhibition of amyloid
aggregation by the addition of F-GQDs was conrmed. In the
presence of F-GQDs, the morphology of the hIAPP aggregates
changed from entangled long brils into short thin brils and
amorphous aggregates. By employing uorescence analysis
using thioavin T, inhibited aggregation with a prolonged lag
time, and reduced uorescence intensity at equilibrium were
demonstrated aer hIAPP was incubated with the F-GQDs.
Based on the circular dichroism spectrum results, the F-GQDs
could inhibit the conformational transition of the peptide
from its native structure to b-sheets. F-GQDs could also rescue
the cytotoxicity of INS-1 cells induced by hIAPP in a dose-
dependent manner.198
6.2.2. O-dot interaction with lipids. Another topic of
interest is the possible interaction between O-dots and lipids or
bio-membranes (Fig. 14b). For many applications such as bio-
imaging, diagnosis, and drug delivery, the interactions
between O-dots and lipids/or bio-membranes are of great
signicance because O-dots may hypothetically inuence the
structure and properties (e.g. membrane permeability) of bio-
logical membranes. Recently, it was shown that CQDs could

































































































View Article Onlineunilamellar vesicles.199 Jelinek and colleagues made signicant
contributions to elucidate the interaction of CQDs with lipids/
membranes.200–202 In one study, they showed that amphiphilic
CQDs could insert into the lipid bilayer of giant vesicles and
induce FRET energy transfer from the CQDs to dyes embedded
in the membrane.203 By conjugating the amphiphilic CQDs with
phospholipids, the same group developed a new probe for the
study of the environment and processes occurring in
membranes.204 The interactions between the amphiphilic CQDs
with actual bacterial cell membranes (not models) were also
studied, in which the emission spectra of CQDs depended on
the identity of the bacterial strains with regard to the spectral
shi and peak intensity. This may offer an opportunity to
identify different species of bacteria using uorescence spec-
troscopy and microscopy.205 Furthermore, the unique interac-
tion of CQDs with bacterial membranes was exploited to detect
bacteria in a biological environment by a different group.206
Recently, Pan and co-workers reported a very interesting study,
whereby the interaction of CQDs with the cell membrane was
exploited to design “caged” CQDs for monitoring intracellular
trafficking via switchable PL.204 In this study, negatively-charged
highly luminescent “bare” CQDs showed reduced PL intensity if
positively charged macromolecules became wrapped around
their surface. Nevertheless, the “quenched” CQDs could recover
their emission through interaction with anionic surfactant
molecules (i.e., anionic amphiphiles or endocytic membranes)
and this phenomenon could be used for monitoring intracel-
lular trafficking.
Studies on the antibacterial activity of CQDs have also been
reported recently.207 The antibacterial activity of these C-dots
was attributed to the destructive interactions between CQDs
with the bacterial cell membranes, which closely depended on
the surface charge on the CQDs.208 To elucidate the cellular
behavior of CQDs, Zhou and coworkers207 carried out a system-
atic study. In this study, it was found that the cellular uptake of
CQDs was a dose-, time- and partially energy-dependent
process, which also to some extent involved passive diffusion.
These CQDs could penetrate the cell membranes by endocytosis
via caveolae-mediated and clathrin-mediated pathways.
Similar to CQDs, graphene quantum dots can also alter the
structure of cell membranes. Jiang and co-workers assessed the
toxicity of graphene oxide (GO) and nitrogen-doped graphene
quantum dots (N-GQDs) on red blood cells (RBCs) through
analysis of hemolytic activity. The morphology of the RBCs
changed and their ATP content was lower aer being exposed to
the different nanomaterials. The structural changes of the RBC
lipid membranes were studied via surface-enhanced infrared
absorption spectroscopy using model membranes. The analysis
of the infrared spectra conrmed that the adsorption of GO
perturbed the integrity of the membrane by extracting the lipid
bilayer, resulting in hemolysis and aberrant-shaped cells. By
contrast, when N-GQDs were tested, the disturbance of the
structure and conformation of the lipid was less, which resulted
in fewer abnormal cells.209
6.2.3. O-dots interaction with nucleic acids. It is important
to examine the interaction between nucleic acids (DNA and
RNA) and different nanomaterials because nucleic acids are2268 | RSC Adv., 2021, 11, 2253–2291responsible for carrying genetic information (Fig. 14c).
Recently, the interaction of CQDs with different types of DNA
structures, i.e. double-stranded DNA (dsDNA) and single-
stranded DNA (ssDNA) has attracted interest. Studies have
shown that two different interaction mechanisms with CQDs
can occur, producing discrete changes in uorescence
behavior.210–212 As an example, Loo et al. prepared a sensing
platform in which CQDs and a uorescently labeled ssDNA
probe (FAMLprobe) were used to identify a specic sequence of
DNA.209 Due to the difference in the interactions of CQDs with
ssDNA and dsDNA, the uorescence of the FAMLprobe (ssDNA)
was effectively quenched by CQDs, unless it had formed dsDNA
by base-pairing with the target DNA.
It is expected that the negative charge of nucleic acids caused
by the phosphate backbone will interact strongly with
positively-charged CQDs through electrostatic interactions.213
The interaction of CQDs with DNA may be so strong that it can
alter the conguration of DNA. Sun and co-workers found that
positively-charged CQDs selectively promoted the trans-
formation of right-handed DNA (B-DNA) into le-handed DNA
(Z-DNA).210 It is believed that in this interaction, CQDs bind
inside the main groove of DNA, as veried by competitive
binding experiments using ethidium bromide, daunomycin,
and Hoechst 33258. It is worth noting that Z-DNA has been
identied as a transient structure that is activated by normal
biological processes such as transcription, DNA supercoiling
and cytosine methylation.215,216 Based on this nding, some
DNA-based logic gates have been designed to exploit the uo-
rescence resonance energy transfer between CQDs and DNA
intercalators. With their high biocompatibility, superior optical
properties and predictable interactions with nucleic acids,
CQDs have also found important applications as delivery vehi-
cles for nucleic acids in a highly efficient manner.214 A study was
reported using uorescent CQDs as an efficient nano-carrier for
siRNA to enable gene knockdown in gastric cancer cells with
promising results.215
As mentioned above, the phosphate groups of DNA provide
a negative charge, and thus the positive charge on the surface of
O-dots is very important for suitable electrostatic interaction.
Without this modication, the interaction between O-dots and
DNA is probably too weak, and thus will lead to rapid release of
therapeutic genes during delivery. Thus, cationic polymers such
as polyethylenimine (PEI) are widely used to provide a positive
charge.216 In 2017, the Yang group prepared a gene delivery
system using CQDs, equipped with PEI and folic acid (FA). They
used gel electrophoresis to ensure the ability of CQDs with PEI
to bind to DNA due to their positive charge. It was concluded
that the composite could be used to transfer plasmid DNA into
cells.217
A recent study on the interaction of GQDs with three
different types of DNA (well-matched DNA (WM-DNA), base-
impaired DNA (AB-DNA) and amino-modied DNA (AM-DNA))
showed that GQD could reduce the melting temperature of
DNA, and thus reduce its stability. It was also observed that the
WM-DNA structure and conformation were not changed, but

































































































View Article Online6.3. The interaction of O-dots with the blood–brain barrier
(BBB)
In many applications, especially for drug and gene delivery
systems, it is important to investigate the behavior of O-dots in
biological environments. One of the important organs in the
human body is the brain. In recent studies, scientists have
concentrated on the ability of O-dots to cross the blood–brain
barrier (BBB), the most important barrier in the central nervous
system (CNS) (Fig. 15b). The BBB acts as a physical barrier and
regulates the passage of designated molecules between the
bloodstream and the brain by either paracellular or trans-
cellular pathways. The BBB hinders the diffusion of many
therapeutic agents from the blood into the brain. The tight
junctions in the BBB have pores with a size of 4–6 nm. There-
fore, nanoparticles that are 4 nm or less in size can cross the
BBB by passing through these gaps.219,220
The mechanisms of BBB penetration can be divided into
active and passive transport routes.221 The passive transport route
is an energy-independent process, for instance, simple diffusion.
Frequently, the passive diffusion of drugs used against tumors
occurs via the enhanced permeability and retention effect
(EPR).222 The active transport routes include receptor-mediated
and adsorption-mediated endocytosis and carrier-mediated
transport, all of which require energy obtained by the hydro-
lysis of adenosine triphosphate (ATP).223 Besides, the trans-
portation of drugs can be enhanced by different NPs and their
specic mechanisms. For instance, the small stereospecic pores
that are employed in the carrier-mediated transport system
restrict the movement of large-molecule drugs.224 However most
CDs have an ultra-small size (1–10 nm) and versatile surface
functionalities,225 which can improve large molecule delivery if
the CDs are covalently conjugated to the drug.226
Pediatric malignant glioma is one of the most common
cancers among children, which is be fatal. Doxorubicin (Dox) isFig. 15 Interaction of O-dots with body fluids and the brain blood
barrier. (a) O-dots can interact with body fluid components, specifi-
cally proteins. (b) O-dots can pass through the BBB via passive and
active transport.
© 2021 The Author(s). Published by the Royal Society of Chemistryan effective drug that can hinder the replication of many
different cancer cells. Nonetheless, Dox frequently causes severe
side effects due to its non-specic attack on healthy cells, such
as congestive heart failure. Thus, the delivery and release of
drugs such as Dox across the BBB into the CNS can selectively
target pediatric brain tumors. Li et al. covalently linked CQDs
with transferrin to efficiently deliver Dox due to the over-
expression of the transferrin receptor (TfR) on the BBB and
cancer cells. CQDs were prepared from raw carbon powder
using a “top-down” approach.227 Then SJGBM2 cells, a pediatric
brain tumor cell line, were used to demonstrate the higher
uptake of the conjugate compared Dox alone, which was
conrmed by counterstaining with Hoechst. Four different
tumor cell lines (CHLA-266, CHLA-200, SJGBM2 and Daoy) were
exposed to 1, 10 and 100 nM of the conjugate and Dox aqueous
solutions. The results showed that 10 nM conjugate solution
gave the highest toxicity to all the pediatric tumor cell lines.
In the same year, based on publications that showed the
importance of transferrin in transporting drugs to the brain
parenchyma228 and brain glial cells,229,230 Li and coworkers
employed zebrash as a biological model to investigate whether
transferring-conjugated CQDs could cross the BBB.231 Zebrash
is a vertebrate species with a high physiological similarity to
humans and genetic homology.232 The advantages of zebrash
include their easy culture, transparent body, and the rapid
formation of the BBB. Zebrash are considered to be a superior
model to mice for studying whether CQDs can pass across the
BBB using transferrin-receptor mediated endocytosis.233,234
CQDs and the CQD/Trans/Dox conjugate were directly
injected into the zebrash heart. However, there was no uo-
rescence in the CNS when CQDs were injected alone. To show
that the lack of uorescence did not result from the low
quantum yield of CQDs, a dye (5-(aminomethyl)uorescein) was
conjugated with the CQDs. The conjugated CQDs with 5-(ami-
nomethyl)uorescein also did not show any uorescence in the
CNS of the zebrash. Therefore, it was concluded that CQDs
alone could not cross the BBB. Similarly, the CQD/Trans/Dox
conjugate was conjugated to a dye to enhance its PL emission.
The CQDs/Trans/Dox conjugate labeled with the dye was
successfully shown to reach the CNS by uorescence spectros-
copy, suggesting that the CQDs could cross the BBB, probably
by TfR-mediated endocytosis.
Although CQDs are promising drug carriers, to some extent
they possess the same limitations in crossing the blood–brain
barrier as small molecule drugs. If CQDs can be prepared from
a precursor that is known to be able to cross the BBB, there is
a chance that the precursor molecules on the CQD surface can
also allow CQDs to reach the brain. In the study by Mintz et al.,
tryptophan CQDs were produced from tryptophan, which is an
amino acid that can cross the BBB via LAT1 transporter-
mediated endocytosis.235 Two types of CQDs were synthesized
using tryptophan and two additional nitrogen dopants, namely
urea and 1,2-ethylenediamine. As mentioned previously, these
CQDs were able to cross the BBB of zebrash (Danio rerio) via
the LAT1 transporter.
In another study, GQDs were used to hinder the brillization

































































































View Article Onlinebrils, causing their disaggregation. Moreover, GQDs could
prevent neuronal cell death and synaptic loss, decrease the
formation of Lewy bodies and Lewy neurites, reverse mitochon-
drial dysfunction, and prevent the neuron-to-neuron trans-
mission of preformed a-syn brils.5,6 In vivo studies showed that
GQDs could penetrate the BBB and protect against dopaminergic
neuron loss induced by preformed a-syn brils, and reduce Lewy
body/Lewy neurite pathology and behavioral decits.236
6.4. O-dot interactions with biological uids
The behavior of O-dots in various biological and body uids is
very important since most reactions in humans and other living
organisms occur in a uid environment (Fig. 15a). Injection of
nanoparticles intravenously or subcutaneously is the most
common route of administration, and therefore exhaustive
testing is required to determine the fate of nanoparticles within
the blood circulation (the main uid within the body) and their
impact on hematopoietic functions and cells.237 Moreover,
studies in simulated physiological condition such as blood at
pH  7.4 and temperature  37 C have shown that CQDs can
be efficient drug delivery systems. As an example, researchers
increased the release rate of Dox in physiological uid by link-
ing carboxymethyl cellulose-hydroxyapatite to CQDs, compared
to the composite without CQDs.238 Therefore, it seems that
CQDs are effective drug delivery systems in physiological envi-
ronments. The study of the interaction of CQDs with plasma
components, especially coagulation-related proteins, is crucial
in the eld of drug delivery. In 2017, the effect of O-dots derived
from Schizonepetae Herba Carbonisata (SHC) on a liver wound
was investigated. The animals treated with O-dots had a shorter
bleeding time compared with the control group. However, the
study of O-dot behavior in plasma requires more research.239
The most abundant protein in plasma is serum albumin. In
2018 Guo and coworkers examined the behavior of O-dots in the
presence of human serum albumin (HSA). The results showed
that the O-dots interacted with HSA through hydrophobic
interactions and hydrogen bonds. A bond was created between
the oxygen or nitrogen atoms in the amino acids present in HSA
and nitrogen and oxygen-containing functional groups in the O-
dots. This binding could change the HSA secondary structure
and disturb the normal function of the protein.240
7. O-dots as a theranostic platform
The distinctive optical features of O-dots make them highly
attractive candidates as imaging reporters combined with drug
delivery and therapeutic applications. Their special properties
allow them to overcome various problems associated with
conventional imaging probes and to provide versatile nano-
platforms with both imaging and therapeutic capabilities.
Herein, we survey the applications of O-dots for theranostic-
enabled drug delivery and therapy (Fig. 16).
7.1. Non-targeted cargo delivery
Although currently there is a trend toward targeted cargo
delivery, non-targeted systems are still useful in some2270 | RSC Adv., 2021, 11, 2253–2291biomedical applications. Moreover, a need for systemic effects
of drugs is another reason. Also, making cargo carriers
responsive to certain stimuli can also be a suitable alternative to
targeted cargo carriers.
CQDs–Dox antitumor drug complexes were synthesized
using a combination of CQDs and Dox through a hydrothermal
method. The surface functional groups of CQDs were connected
to Dox through electrostatic interactions, and the CQDs–Dox
complexes could be transported into cells via both endocytosis
and passive diffusion. Moreover, these complexes exhibited pH-
sensitive Dox release behavior, and enhanced antitumor activity
compared to Dox alone.241 In another study, hollow CQDs with
a diameter of ca. 6.8 nm and pore size of ca. 2 nm were inves-
tigated as a delivery carrier for Dox. The Dox-hollow CQD drug
delivery system (DDS) could be rapidly internalized by cells, and
the release of the drug was regulated by pH. These hollow CQDs
showed promise for both cell imaging and cancer therapy due to
their nanostructure and photoluminescence properties.242 Li
and co-workers prepared CQDs from ginger as a precursor,
which were efficient without any drug cargo to kill hepatocel-
lular carcinoma cells (HepG2) and showed lower toxicity
towards normal mammary epithelial cells (MCF-10A) and
normal liver cells (FL83B).243 They prepared the ginger CQDs via
the simple hydrothermal treatment of ginger juice. Their CQDs
selectively killed HepG2 cancer cells over other cancer cells,
including human lung cancer cell line (A549), human breast
cancer cell line (MDA-MB-231) and human cervical cancer cell
line (HeLa). Western blot analysis revealed that the CQDs up-
regulated the expression of p53 protein only in the case of
HepG2 cells. In addition, they found that the uptake of CQDs by
HepG2 cells increased the intercellular production of reactive
oxygen species (ROS) up to 18.2-fold, which led to the induction
of apoptosis, whereas in other cells, the ROS level was almost
unchanged aer treatment with 1.11 mg mL1 CQDs. A subse-
quent in vivo study in a nudemice tumormodel showed that the
CQDs could effectively inhibit the growth of tumors (3.7  0.2
vs. 104  14 mg with and without treatment aer 14 days).
Moreover, Yuan et al. reported that CQDs prepared from
milk showed pH-dependent release behavior of Dox. Briey, the
negatively charged Dox was effectively bound to the positively
charged CQDs. Compared with the free Dox, CQD–Dox
demonstrated greater cytotoxicity towards cancer cells, whereas
it showed lower toxicity towards a normal mouse broblast cell
line.244
Khodadadei et al. produced 10 nm-sized nitrogen-doped
GQDs (N-GQDs) with 10 graphitic layers, which could be
loaded with methotrexate (MTX) to create a drug delivery
system. The results showed that the GQDs were robust nano-
carriers with higher anti-tumor activity, and could extend the
cytotoxic effects of the loaded drug for a longer time.245 Some
et al.246 used curcumin (Cur) as an anti-cancer drug. They
showed that curcumin could attach to GQDs by interacting with
the polar oxygen-containing groups at the edge of the GQDs.
They found that the presence of more surface oxygen functional
groups increased the loading capacity of the GQDs for curcu-
min. This occurred at pH 9, which is much higher than the
physiological pH of 7.4, indicating that Cur was unlikely to© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article Onlinedissociate in the extracellular environment or in normal healthy
cells. They observed dissociation of Cur from the GQDs at the
lower pH values typical of cancer cells. Up to 85% was released
within 24 h at pH 5, compared to only 5% at pH 9 and 9.8% at
pH 7.5. The GQD-Cur complex exhibited good ability to kill
human colon adenocarcinomaHCT 116 cells, killing 90% at 100
mg mL1, compared with 70% for Cur alone. The in vivo tests
showed a much lower tumor volume and mass aer 14 days in
the mice with HCT tumors. The tumor volume for the mice
treated with GQD-Cur was 200 mm3 (almost no increase in
tumor size) compared to 1000 mm3 for the control mice.7.2. Targeted cargo delivery
Some of the side effects of treatments are due to their unspecic
functions and targets. Many drugs can be taken up by other cells
rather than the intended cells. Moreover, this unspecic uptake
also causes low concentrations of drugs in the intended sites,
which would be below the therapeutic levels, and therefore, the
real targets would not uptake a sufficient amount of drug. In
this case, the primary concentration of the drug has to increase
in order to provide a sufficient concentration at the diseased
sites. This problem indicates a need for more specic therapy
methods. Since biological systems demonstrate specic char-
acteristics and properties, it is possible to target them for better
therapies and treatments. Moreover, a suitable platform is
needed for functionalization to become sensitive, specic and
responsive to biological systems besides loading cargo. O-dots
have shown promising properties in the eld of targeted cargo
delivery due to their capacities in being hybridized and func-
tionalized properly with other nanoparticles, polymers,
biomolecules, etc.
Individual O-dots contain various functional groups on their
surface. For example, the carboxyl groups of O-dots can be
functionalized by N-hydroxysuccinimide (NHS) esters to conju-
gate with lysine residues in protein structures. O-dots have been
used to label actin for actin polymerization studies, transferrin© 2021 The Author(s). Published by the Royal Society of Chemistryreceptors were probed with uorescent O-dot-labeled trans-
ferrin, and albumin-O-dot tags have been used for in vitro and in
vivo signaling studies. This strategy is most suitable for CQDs
with a high QY, which are prepared from citric acid with
carboxyl functional groups. The conjugation of proteins with
CQDs generally leads to an increase in uorescence intensity
and lifetime owing to the reduction of intramolecular dynamic
uctuations. Moreover, protein tagging can lead to less uctu-
ations in the uorescence and more efficient use of excitation
photons, which can be determined by single-molecule uores-
cence measurements.247,248
The most common non-covalent interactions of CQDs occur
between organic molecules or uorophores. These interactions
are hydrogen bonds, dipole–dipole interactions, hydrophobic
interactions, van der Waals forces, electrostatic forces, and p–p
stacking. Moreover, several factors such as pH, metal ions and
organic solvent play a critical role in the attachment of organic
molecules and uorophores to CDs.249 P-CQDs/HA-Dox is one
example of non-covalent interactions between positively
charged polyethylene imine-modied CQDs (PEI-CQDs) and
negatively charged hyaluronic acid (HA)-conjugated doxoru-
bicin (Dox). These nano-hybrids were prepared via an electro-
static self-assembly method and used for the detection of
hyaluronidase (HAase) activity in drug delivery.250 Moreover,
PEI-CDs could also form a complex with folic acid (FA) via non-
covalent binding, which was an effective approach for detecting
and targeting folate-receptor (FR)-positive cancer cells. The
uorescent CQDs were produced using a hydrothermal method,
and their surface was coated by positively-charged polyethylene
imine (PEI), which allowed further conjugation with FA by
electrostatic interaction. The FA-targeted PEI-modied CQDs
(FA-PEI-CQDs) could act as a turn-on uorescent nanoprobe in
FR-positive cancer cells.251,252 Furthermore, the conjugation of
PEI with CQDs led to positive charges on the CQD surface,
which facilitated electrostatic interactions between the CQDs
and DNA.253 Carboxyl-rich CQDs can be alkynylated using an

































































































View Article Onlinecarbonyldiimidazole. Furthermore, Cu2xSySe1yNCs have been
used as catalysts in the click reaction between alkynylated CQDs
and azido-DNA for the preparation of modied CQDs. Cova-
lently bonded DNA-CQDs can be produced by a copper(I)-cata-
lyzed alkyne–azide cycloaddition click reaction (CuAAC)
catalyzed by Cu2xSySe1yNCs. Research showed that DNA-
modied CQDs are useful in biosensing and bioimaging
approaches.88,254 Aptamer-based spectrouorometric methods
provide a sensitive approach for the detection of cancer cells.
CQDs modied with the AS1411 aptamer act as a sensitive and
selective signal enhancer for the spectrouorometric detection
of various target cancer cells. AS1411is a nucleolin-specic
aptamer for the detection of nucleolin, which is over-
expressed on the surface of cancer cells. The aptamer mole-
cules are physically wrapped around CQDs. Incubation of target
cancer cells in a CQD-aptamer solution led to an enhancement
in the uorescence intensity.255,256 The functionalization of
CQDs with the nuclear localization signal peptide (NLS–CQDs)
is a useful strategy for the transportation of Dox into cancer cells
to improve the anticancer effect of this drug. Dox was covalently
conjugated with NLS–CQDs (Dox–CQDs) via an acid-labile
hydrazine bond, which was degraded in the weakly acidic
intracellular milieu and showed superior suppression of tumor
growth.257,258 A system of pH/redox dual-responsive CQDs
(CQDs-RGD-Pt(IV)-PEG) could act as uorescent imaging tar-
geted nanocarriers. RGD peptide acted as an active targeting
ligand and cisplatin(IV) as a prodrug. They were used for
extracellular-triggered tumor targeting for improved anticancer
drug delivery. The hydrolysis of the benzoic-imine bonds at the
low extracellular pH led to exposure of the inner targeting RGD
peptide, followed by effective uptake by interaction with the
integrin avb3 (ligand–receptor) on the cancer cells.259–261
Polymer-coated CQDs (p-CQDs) are a new class of uorescence
nanoprobes with an ultra-small size, good biocompatibility, and
high water solubility, which can be synthesized via direct sol-
vothermal transformation. They can be covalently conjugated
with I6P8, which is a fragment of interleukin-6 (IL-6), identied
by the phage display technique, and can specically bind to the
IL-6 receptor. This receptor is expressed on both brain capillary
endothelial cells and various cancer cells such as glioma.
Conjugation of p-CQDs with I6P8 (cys-I6P7) led to improve-
ments beyond that expected from passive targeting. The
encapsulation of drugs such as Dox can be stabilized by these
nanocarriers, allowing them to cross the BBB and deeper
penetration of drugs into brain tumors. In summary, blocking
the oncogenic function of IL-6 and the pH-responsive release of
the loaded Dox are the main mechanisms for the improved anti-
cancer effects.262,263 A nuclear-targeted drug delivery vehicle was
fabricated by immobilizing a nuclear localization signal peptide
(NLS) onto CQDs (NLS–CQDs). Through an acid-labile hydra-
zone bond, Dox was coupled onto NLS–CQDs (NLS–CQDs–Dox)
and released in the weakly acidic intracellular compartment.
NLS–CQD–Dox was mainly located in the nucleus and could
efficiently induce apoptosis in human lung adenocarcinoma
A549 cells. Moreover, NLS–CQD–Dox exhibited enhanced ability
to inhibit tumor growth in vivo compared with free Dox in an
A549 xenogra nude mouse model.2642272 | RSC Adv., 2021, 11, 2253–2291Folic acid (FA)-conjugated GQDs could also be loaded with
Dox. This nanoassembly could unequivocally distinguish
cancer cells from normal cells, and efficiently deliver the drug to
target cells. The inherently stable uorescence of GQDs enabled
real-time monitoring of the cellular uptake of the Dox–GQD–FA
nanoassembly and the consequent release of Dox. The nano-
assembly was rapidly internalized by HeLa cells via receptor-
mediated endocytosis, while the Dox release and accumula-
tion were improved.265
Justin et al.266 used GQDs as a non-toxic imaging agent to
track the diffusion of drugs frommicroneedle arrays. Lidocaine
hydrochloride (LH) was attached by p–p stacking to the GQDs
and could passively diffuse through the microneedles due to its
small molecular weight. They also coated GQDs with bovine
serum albumin (BSA) as a large molecular weight cargo. GQD–
LH also become loaded into chitosan to be used in a micro-
needle array for delivery. They used iontophoresis to stimulate
the release of the BSA, which showed an increase in release rate
from to 94.5% compared to 7.6% by passive diffusion.
Rare earth up-conversion nanoparticles and GQDs have
attracted much interest in biomedicine, but they all have some
inherent limitations as nanocarriers for in vivo drug delivery.
One study reported a new concept for the fabrication of a GQD-
rare earth up-conversion hybrid via coordination between rare
earth metal ions and histidine, and attachment to
octadecylamine-functionalized GQDs with uoride ion
replacement and subsequent hydrothermal treatment. The
hybrid had a cage-like nanostructure with a mean particle
diameter of 46.2 nm, comprising several layers of graphene
sheets plus NaYF4:Yb,Tm nanocrystals. It showed high stability
in physiological buffer and 140-fold enhancement of up-
conversion luminescence. This biomimetic drug delivery
system was composed of the hybrid plus gold nanoparticles as
the core and MGC-803 cell membranes as the shell, with a Dox
loading capacity of 461.2%. It showed both pH and light-
responsive drug release and carried out chemo/photothermal
therapy with higher anticancer activity than free Dox.267
In another study, a composite of GQDs and Fe3O4 was
prepared and further conjugated with concanavalin A (a lectin
protein) to produce GQD-ConA@Fe3O4 nanocomposites. These
were employed for both the recognition of HeLa cancer cells
and release of drugs. To study their capability to preferentially
recognize HeLa cancer cells over normal endothelial cells, an
electrochemical method was employed. These nanocomposites
were deposited on a Pt electrode, which allowed the assessment
of the dynamic linear range (5  102 to 1  105 cells per mL),
and a detection limit of 273 cells per mL. Also, these nano-
composites could function as magnetically controlled nano-
carriers for loading and releasing Dox. The in vitro results
showed that the Dox concentration in HeLa cells was more than
doubled in the presence of an external magnetic eld due to the
presence of Fe3O4 within the nanoplatform. The cytotoxicity in
HeLa cells was 13% higher than normal cells because of the
selective targeting by ConA. Thus, the GQD-ConA@Fe3O4
nanocomposites are a promising theranostic platform for

































































































View Article Online7.3. Gene therapy
Gene therapy is considered a promising treatment for many
diseases, but some barriers limit its clinical translation. Gene
therapy involves the delivery of nucleic acid-based therapeutic
agents into cells to modify the expression levels of various
genes. Depending on the type of agent they can be activated in
the cell nucleus or the cytoplasm. Genes, their expression,
translation and transcription are a complicated system and
their manipulations may cause serious implications on the
functions of biological systems. Moreover, transferring
a desired gene to the target properly without any damage to the
gene is another limitation. Delivering other nucleic acids will
also affect gene regulations in a complex manner. Therefore,
gene delivery systems should be multifunctional besides being
specic for certain targets and protective for their contents.
Accordingly, GQDs and CQDs present a suitable function for
this purpose due to their physiochemical properties. Gene
delivery systems based on GQDs and CQDs should interact
properly with nucleic acids, precisely deliver them to targeted
cells, protect the nucleic acids from environmental conditions,
not disrupt gene regulatory systems or other physiological
process and cause proper gene expression or regulation. The
parameters involved in efficient gene delivery are discussed
below.269
The success of gene therapy largely relies on the effective-
ness of safe and efficient gene delivery into the target cell
without any damage to the structure of the nucleic acids. A
review of the literature from 2004 to date shows that the use of
carbon-based nanomaterials for in vitro and in vivo gene
delivery has steadily increased.270,271 Among them, O-dots can
deliver numerous types of therapeutic nucleic acids in order to
modulate the gene expression prole of cells. Two main
approaches are used to carry out this goal. In the rst
approach, transcriptionally procient DNA is delivered into
cells to replace a copy of a defective or missing gene, and thus
make up for the deciency of the encoded protein. In the
second approach, various therapeutic nucleic acids are used to
regulate gene expression at different levels, which can be
antisense oligonucleotides (AONs), small interfering RNA
(siRNA), short hairpin RNA (shRNA) or microRNA (miRNA).
These are used to inhibit or destroy the expression of
unwanted genes.272
An efficient carrier for gene delivery should be capable of
binding to nucleic acids properly and protecting them from
environmental hazard conditions. These nanocarriers should
be able to preserve the genetic materials during transportation,
overcome extracellular and intracellular barriers, and deliver
the functional form of the nucleic acid into the target cells in an
intact manner.273
Several important physiochemical parameters, including the
surface charge, size, shape and surface chemistry of the carrier
should be optimized to produce a nano-gene delivery system
(Fig. 17). By adjusting these factors, the fate of nanocarriers
inside the body can be rationally tailored, and accordingly the
nal success of gene therapy can be realized.274© 2021 The Author(s). Published by the Royal Society of Chemistry7.3.1. Physiochemical parameters in gene therapy
nanocarriers
7.3.1.1. Surface charge. It is important to study the stability
of nanocarriers, their cellular uptake mechanism, and their
possible cytotoxicity. The overall surface charge probably has
the most important role in facilitating these processes prop-
erly.275 Because nucleic acids (DNA, RNA, and ODN) possess an
overall negative charge due to the phosphate groups in their
backbone, they cannot pass across cellular membranes by
simple diffusion, and therefore they require carrier systems,
which can form complexes, leading to improved transportation
across biological membranes. These polyplexes overcome the
electrostatic repulsion between nucleic acids and the negatively
charged cell membrane, and thereby expedite their internali-
zation into cells.273 One simple approach to attach genetic
materials to carriers is based on the electrostatic interactions
between positively charged nanocarriers and nucleotides.276
Both charge polarity and charge density can affect the
cellular uptake of nanoparticles, while simultaneously affecting
their cytotoxicity. Positive surface charges combined with
neutral or negative charges can improve the cellular uptake of
nanoparticles allowing adhesion to the cell membrane in both
phagocytes and non-phagocytic cell lines.277
Carriers with the highest positive charge density can be
taken up to a higher extent at a faster rate.275 Additionally, the
surface charge of nanocarriers determines the mechanism of
cellular endocytosis. Nanocarriers can be internalized in cells
via two pathways, i.e. clathrin-mediated endocytosis and
caveolae-mediated pathways. Positively charged carriers use the
rst pathway, while carriers with a negative surface charge can
be taken up through the second one.278
In comparison with the effects of negatively or neutral
charged nanoparticles, positively charged nanoparticles exhibit
greater overall cytotoxicity.277 Positively charged species can
increase the Ca2+ inux into cells, and thereby inhibit their
proliferation, disturb the structure of the lipid bilayer and its
uidity.279 Nanoparticles with a higher surface charge are more
resistant to the formation of aggregates due to their strong self-
repulsion.274 It is clear that the surface charge of the carriers will
be affected by gene loading. Due to the electrostatic interaction
between the positively charged carrier and negatively charged
nucleic acids, the surface charge of the complex will be partly
neutralized.280 The carrier/DNA ratio (known as the N : P ratio)
usually imposes a complex charge, which increases to more
positive values with an increase in the N : P ratio. However, at
a lower N : P ratio, the formed complex may be incapable of
effectively interacting with the cell membrane.281
7.3.1.2. Size. Another necessary factor in gene delivery is the
size of nanocarriers, which can noticeably inuence their
colloidal stability, cellular uptake, transfection efficiency, resi-
dence in circulation, and the rate of clearance.274 In vitro
experimental results revealed that nanoparticles are taken up by
cells more efficiently as their size decreases.282 Nanoparticles
with a size of around 20 nm can be taken up via cells in an
endocytosis-independent manner. Longer circulation times in
vivo can be achieved by the administration of nanoparticlesRSC Adv., 2021, 11, 2253–2291 | 2273
Fig. 17 Gene therapy based on graphene quantumdots. Several parameters should be considered in gene delivery and gene therapy. (a) Number
of layers and surface modification of GQDs play a key role in the loading capacity of the particles. (b) Size, electrical charge, hydrophobicity and
surface chemistry of GQDs are important parameters in their structural stability and longer circulation. (c) Electrical charge, condensation, nature
and amount of cargo, synthetic method and modifications would change the size of the particles, which leads to altered performance. (d)
Nucleic acid loading and changes in size determine the net charge of the particles. (e) Different properties of the GQD complex determine the

































































































View Article Onlinewith a size smaller than 200 nm. Smaller nanoparticles
demonstrate lower clearance and better delivery to tumor
tissues in comparison with larger nanoparticles, while they are
not accumulated in other organs, such as the lungs, liver and
spleen at this level. On the other hand, particles larger than
200 nm are rapidly removed by the liver, spleen and lungs.282 In
the case of O-dots, size also has an important effect on
amphiphilicity, and thus smaller sheets are more hydrophilic2274 | RSC Adv., 2021, 11, 2253–2291due to their higher edge-to-area ratio. Moreover, smaller gra-
phene sheets show better colloidal stability because of their
higher charge density.283 The layer number is another param-
eter that should be considered in the design of O-dots since this
governs the specic surface area and bending stiffness.284 By
decreasing the number of layers to one or more, the loading
capacity of the cargo will be improved. The size of the carrier

































































































View Article OnlineThe electrostatic interaction between the carrier and nucleic
acids leads to condensation or compaction of the genetic
material. The degree of condensation affects the size variability.
However, the size of the complex can be altered by changing the
structure of the cationic carrier, the N : P ratio and also the
fabrication method. For instance, by increasing the N : P ratio
during complex formation, the complex size will show
a decreasing trend due to more efficient condensation of the
loaded nucleotides.286 Therefore, the N : P ratio during
complexation should be precisely optimized before
transfection.287
7.3.1.3. Shape. The shape of nanocarriers also governs their
transportation across biological barriers and their fate inside
cells.282 Spherical-shaped nanoparticles smaller than 100 nm
are taken up more efficiently in contrast to rod-shaped nano-
particles, and therefore lower cell uptake occurs as the aspect
ratio of nanorods increases.
7.3.1.4. Surface chemistry. It is known that the surface
chemistry of nanocarriers affects their biocompatibility, circu-
lation within the body, and their interaction with the cells. The
blood half-life of nanocarriers is governed by their surface
hydrophobicity. As the hydrophobicity of the surface increases,
more proteins including opsonin bind to the surface and
complexes would be taken upmore rapidly, which subsequently
leads to a shorter circulation time.277 Nanoparticles with
a hydrophobic surface diffuse into cells and tissue more quickly
than that with a hydrophilic surface due to the hydrophobic
nature of the cell membrane.282 Many methods have been
employed to modify the surface of nanoplatforms to improve
the biocompatibility, circulation time, cellular uptake and
thereby the transfection efficiency of nanocarriers.274 Since O-
dots are intrinsically non-cationic, different modication
approaches such as modication with PEI, chitosan, peptides,
dendrimers, and PEG derivatives have been explored to provide
cationic surfaces for a better interaction with anionic nucleic
acids.
7.3.2. O-dots in gene delivery. Ghafari and coworkers
prepared peptide-modied GQDs with two different (green and
red) emission colors, and tested them for gene delivery and
nuclear targeting applications and cellular tracking.288 The
GQDs were physically linked to the MPG-2H1 chimeric peptide,
which contained three different amino acid sequence motifs.
These motifs were designed to carry out three different func-
tions, including, DNA packaging, endosomal escape, and
nuclear targeting. These modied O-dots facilitated cell
tracking and showed improved transfection of the luciferase
plasmid into HEK 293 embryonic kidney cells.
In another study, researchers prepared a multifunctional
nanocomposite containing poly(L-lactide) (PLA), polyethylene
glycol (PEG) and GQDs (f-GQDs) for the rapid imaging analysis
of intracellular microRNAs (miRNAs), and combined gene
delivery for improved therapeutic effects. The functionalization
of GQDs with PEG and PLA enabled the f-GQDs to be stable in
the physiological environment and also to have constant pho-
toluminescence over a broad pH range, which is required for
cell imaging. The f-GQDs possessed outstanding biocompati-
bility, low cytotoxicity, and protection of the cargo. The f-GQDs© 2021 The Author(s). Published by the Royal Society of Chemistrycould efficiently transport a miRNA probe for intracellular
miRNA imaging into HeLa cells. The large surface area of the
GQDs could concurrently bind to the agents targeting miRNA-
21, which led to the inhibition of cancer cell growth.289
Carbon quantum dots can also be applied as gene delivery
platforms, especially N-doped CQDs, which generally possess
a high quantum yield. For instance, N-CQDs fabricated using
citric acid and tryptophan (Trp) were found to have good
biocompatibility and capability to be functionalized with poly-
ethyleneimine in order to deliver siRNA against the anti-
apoptotic protein survivin into human gastric cancer cells.
The siRNACQDs@PEI complex was rapidly taken up by cells and
down-regulated the expression level of survivin mRNA. Flow
cytometry showed that the nanocomposites could cause
a mixture of early apoptosis, late apoptosis, and necrosis in the
target cells.290
Furthermore, uorescent CQDs were attached to siRNA
against polo-like kinase-1 (Plk1) to strongly down regulate the
expression of Plk1, an essential regulator of mitosis. The
required amount of FCNs was only 1/30 of that of gold
nanoparticles to deliver an equal amount of siRNA. They
showed strong antitumor effects in vitro and in vivo by gene
silencing, which was even greater than siRNA transfection by
the positive control Lipo2000/siPlk1.291
Kim et al. (2017)292 reported the use of CQDs as a functional
siRNA delivery system for effective gene knockdown in vitro and
in vivo. They showed that CQDs increased the uptake of siRNA
by tumor cells via endocytosis, accompanied by low cytotoxicity
and interesting effects on the immune system. Fluorescence
images veried the localization of the CQDs in the cytoplasm
and release of siRNA within 12 h. The functional siRNA delivery
system mediated by CQDs-PEI was used in an in vivo mouse
model, with good gene knockdown efficacy and protection of
the siRNA from degradation in vivo. Recently, Yang et al.
(2017)293 reported a simple one-step hydrothermal carboniza-
tion procedure for the synthesis of positively charged CQDs
using PEI and FA as carbon sources. The cytotoxicity experi-
ments conrmed that the toxic effects of PEI were lower in the
presence of CQDs, and the composite could be useful as a probe
for the selective imaging of folate receptor (FR)-positive cancer
cells compared to normal cells. The surface of CQD/pDNA had
a positive charge, which facilitated the interaction with the
weak negative charges of the cell membrane, suggesting that
the surface of CQDs could efficiently capture pDNA molecules.
To study gene expression in vitro, they used transfection with
CQDs, and pDNA encoding enhanced green uorescent protein
(EGFP) in 293T and HeLa cells. These results showed that the
positively-charged CQDs could efficiently transfect cells and
could be useful for gene therapy.
Hyaluronic acid (HA) is a natural, biodegradable, biocom-
patible polymer that specically recognizes and binds to CD44,
a receptor expressed on the surface of cells, including tumor
cells. HA was used in the construction of an O-dot-based nano-
vehicle, which can be useful in tumor therapy.294 Wang et al.295
described the synthesis of CQD particles, in which HA was
utilized as the carbon source and PEI as a passivation agent

































































































View Article Onlinethis study, the presence of HA improved the biocompatibility of
the CQDs and the cationic amine groups on PEI helped DNA
condensation and triggered endosomal release once internal-
ized. Gel retardation and ethidium bromide (EtBr) exclusion
assays suggested that the minimum C/P ratio required to
inhibit DNA migration was equal to 1, while analysis of the
particle size and zeta potential suggested that a C/P ratio above
6 was the most suitable for transfection. In comparison to PEI,
these materials demonstrated lower cytotoxicity and up to 50-
fold higher transfection efficiency in the presence of 10%
serum. In vitro experiments using BSA protein binding, ow
cytometry, and confocal microscopy also showed effective gene
delivery. The uorescent properties of these particles allowed
the monitoring of the DNA internalization process, while an HA
competition assay showed the specic ability of HA-QDs to
identify cells overexpressing CD44. Different aspects of the use
of GQD in gene delivery is shown in Fig. 17.7.4. Bioimaging applications
Other major application of GQDs and CQDs is bio-imaging.
This application is based on their photoluminescence proper-
ties,296,297 although they can be hybridized with other particles
for use in other imaging modalities.298–300 Bioimaging can both
provide basic knowledge about biological systems and used in
diagnostic methods. Bioimaging is one of the pivots of thera-
nostics, and since GQDs and CQDs are suitable cargo carriers
and demonstrate other therapeutic activities including photo-
thermal therapy and photodynamic therapy, showing bio-
imaging capabilities, they are promising theranostic agents.
Luminescent nanoparticles have been widely used for bio-
imaging applications and visualizing living cells. However,
their potential toxicity is still a problem, which may limit the
bio-imaging application of many luminescent nanoparticles. O-
dots possess low toxicity and good biocompatibility, coupled
with stable PL, and therefore they are ideal candidates for both
in vitro and in vivo bio-imaging. In this section we discuss the
recent progress in bio-imaging applications both in vitro and in
vivo.301
7.4.1. In vitro imaging. Many studies have reported the use
of O-dots for in vitro bio-imaging.302–304 In several applications,
QDs have been shown to be superior to organic dyes and uo-
rescent proteins due to their enhanced brightness, photo-
stability, imaging sensitivity, and good resistance to metabolic
degradation.305 Semiconductor QDs such as CdSe with a core–
shell structure (e.g. CdSe/ZnS) have been used for in vivo/in vitro
bio-imaging.306 However, the toxicity of cadmium-containing
QDs is a concern due to their long-term accumulation in
tissues and organs. Thus, to compare the ability of CQDs in bio-
imaging with classical semiconductor QDs (CdSe/ZnS),
researchers used CQDs prepared via nitric acid treatment of
carbon soot and then high-temperature treatment with
PEG1500N to attach oligomeric PEG. They found that the CQDs
were more biocompatible and performed equally well in bio-
imaging in comparison with CdSe/ZnS QDs. Based on uores-
cence images of CQDs and CdSe/ZnS commercial QDs under
high dilution conditions, the CQDs showed good and non-2276 | RSC Adv., 2021, 11, 2253–2291blinking uorescence properties (QY of 20% at an excitation
wavelength of 440 nm). One advantage of CQDs is that they have
a smaller size compared to the CdSe/ZnS commercial QDs. The
size of CQDs is less than 10 nm, while that of commercial QDs is
larger than 20 nm. The smaller sizes of CQDs offer the oppor-
tunity to image small biological structures and also a lower
volume will be needed for in vivo injections.305 Cao et al. fabri-
cated CQDs with strong luminescence upon two-photon exci-
tation in the NIR region, and used poly(propionyl ethylenimine-
co-ethylenimine) for surface modication. They conrmed that
the two-photon absorption cross-section of the puried CQDs
was comparable with semiconductor QDs. These CQDs were
water-soluble with a size less than 5 nm. The luminescence
intensities of the CQDs depended on the square of the power of
the excitation laser (pulsed infrared laser), conrming two-
photon excitation. Aer incubation of human breast cancer
cells (MCF-7) with the CQDs and excitation with 800 nm laser
pulses, the cells could be visualized under a 2-photon uores-
cence microscope. The CQDs labeled the cell membrane and
the cytoplasm without localizing in the nucleus.
The accumulation of CQDs inside cells can be improved if
they are conjugated with TAT, a human immune deciency
virus-derived cell-penetrating peptide. TAT-conjugated CQDs
were able to penetrate the cell nucleus.307 The surface passiv-
ation of CQDs for bio-imaging can affect their optical proper-
ties. For example, CQDs were prepared by microwave treatment
of maltose, and passivated with dilute NaOH solution. The
NaOH solution produced –OH groups on the sp2 hybridized
carbon atoms, which increased the QY of the CQDs. It was
found that these CQDs were taken up by the cells and produced
a green uorescence emission, while the cell viability was
unaffected even aer 24 h incubation.308
In other experiments,309 surface passivation could change
both the uorescence intensity and the emission wavelength.
The presence of –OH groups can create hydrophilic CQDs,
which are benecial for bio-imaging applications. For example,
CQDs with a particle size of 2–6 nm and a QY of 3% were
produced by reuxing soot with nitric acid. The oxidation of the
soot with nitric acid formed both –OH and –CO2H groups on the
CQDs, making them negatively charged and hydrophilic. The in
vitro experiments showed that the CQDs with no further
passivation were taken up into the cells and released uores-
cence. Under UV irradiation, the cells emitted blue-green uo-
rescence, and under blue excitation, a yellow emission was
observed in the sample, whereas the sample without CQDs was
colorless under the abovementioned excitations.310
When CQDs are puried by dialysis, the dialysis tube pore
size or its molecular weight cut-off (MWCO) has a substantial
inuence on the emission characteristics of the CQD solution.
For instance, in one study,311 the effect of the dialysis
membrane molecular weight cut-off varying from 3500 to
14 000 Da was examined, and it was found that the excitation
wavelength for the oxidized CQDs changed for the different
pore sizes, which emitted at different wavelengths in the range
of 360 to 460 nm. The CQDs from membranes with MWCO >
3500 Da (up to 7000 Da) had similar emission intensities, while

































































































View Article Online14 000 Da had a reduced emission intensity. The CQDs that
were collected by the membrane with an MWCO of less than
3500 Da had a low QY, and were contaminated with salts. The
CQDs obtained from dialysis with an MWCO of 3500–7000 Da
had the best optical properties.311
Furthermore, oxidation has a strong effect on the PL features
of CQDs. For instance, in chemically produced GO thin lms in
which isolated sp2 clusters were formed in an sp3 matrix of
carbon–oxygen bonds, greater localization of the electron–hole
pairs and better radiative recombination were observed, and the
PL intensity was inuenced by the reduction treatment. The
reduction process altered the small sp2 clusters, and therefore,
altered the PL intensity. The PL in graphene can be adjusted by
engineering its sp2 clusters by controlled oxidation.312 Similar
results were found by Hu et al.,313 who reported that the addi-
tion of oxidized branched polyethylene imine (BPEI) improved
the band gap by modifying the oxygen–carbon matrix of the
CQDs. The CQDs prepared through oxidation and hydrothermal
treatment using BPEI, with a diameter of 3–4 nm could provide
a QY as high as 54.3%. Incubation of the CQDs with MCF-7 cells
and excitation at 405 nm showed luminescence inside the cells
dispersed throughout the cytoplasm. The PL released from the
CQDs did not decrease during 30 min excitation, indicating low
photobleaching and good photostability.313
Larger carbon nanoparticles can also show uorescence, for
instance CQDs with a mean particle size of 70 nm can emit
uorescence and could be utilized for bio-imaging.314 The
uorescent CQDs were prepared via hydrothermal treatment of
cocoon silk. During the hydrothermal treatment, the silk bers
were rst cut into shorter ones, and then by heating at 200 C
were converted to asymmetrical polymeric fragments, and lastly
to larger CQDs. The human cervical cancer (HeLa) cells incu-
bated with the CQDs showed intracellular uorescence.
Confocal laser scanning microscopy images showed uores-
cence in the perinuclear areas of the cytosol, conrming the
effective uptake of the CQDs into the cells. These CQDs were
used for in vivo tissue imaging of human tumor xenogras
(MCF-7) in nude mice. The uorescence emission observed in
the tumor conrmed the permeability of the CQDs, while they
showed low photobleaching and no blinking.314
Another valuable feature of CQDs for bio-imaging applica-
tions is their photostability. For example, the changes in PL
intensity of the CQDs inside COS-7 cells were studied aer
incubation for 24 h. The COS-7 cells became bright, which
revealed that the CQDs entered the cells, and the CQDs were
able to label both the cell membrane and the cytoplasm of COS-
7 cells. There was no apparent decrease upon continuous exci-
tation for 10 min. This result was ascribed to the low photo-
bleaching and high photostability of the CQDs.315
CQDs generally possess low cytotoxicity, even if they have
been obtained from noxious components. For instance, CQDs
prepared from halophenols (a group of industrial pollutants)
were applied as uorescent labeling agents. Aer incubation of
the CQDs with HeLa cells and excitation with a 405 nm laser,
the cell membrane and perinuclear cytoplasm showed uores-
cence, while the signal inside the cell nucleus was weak. No
morphological damage was observed in the cells aer© 2021 The Author(s). Published by the Royal Society of Chemistryincubation with the CQDs, which signied their low cytotox-
icity.316 Plants, fruits and food products such as orange juice,317
apple juice,318 gelatin,319 milk,320 soy milk,321 honey,322 and egg117
have all been used as a carbon source for the preparation of
CQDs. It is thought that the use of natural products and food-
stuffs may lead to lower toxicity of the resultant CQDs for
biomedical applications. Mehta et al.323 used Saccharum offici-
narum juice as the carbon source for the fabrication of CQDs.
These CQDs were used for cell imaging in E. coli (bacteria) and
S. cerevisiae (yeast). The laser confocal uorescence microscopic
images showed that different colors (red, green and blue) could
be observed in the labeled bacteria and yeast cells using 40 mg
mL1 of CQDs. In the confocal images of E. coli, the CQDs were
well distributed in the membrane and cytoplasm. The CQDs
were taken up by the yeast cells via an endocytosis mechanism.
The CQDs were located in the yeast nucleus, but the yeast cells
maintained >90% viability.323 Orange juice was used to make
CQDs via a hydrothermal process, exhibiting a QY of 26%.
These CQDs were used as imaging probes in human osteosar-
coma (MG-63) cells, where they accumulated in the cytoplasm
but not the nucleus. The PL intensity did not decay over
a continuous excitation period.324
N-doped CQDs can be prepared by doping with various
nitrogen-containing molecules such as diamine to increase
their QY for bio-imaging probes. N-doping resulted in a QY as
high as 36.3%. Fluorescent images (355 nm excitation) of HeLa
cells showed that their cytoplasm was brighter than that with
non-doped CQDs, indicating that labeling with N-doped CQDs
can be performed at lower doses. Continuous UV exposure
caused the uorescence of the non-doped CQDs to be bleached
aer 15 min, while the uorescence of the N-doped CQDs was
still bright aer the same period.325
Stem cells are fundamental to the understanding of embry-
onic development and tissue regeneration because they can give
rise to several progenitor cells, which can in turn differentiate
into cells of different tissue types.326 Due to the generally
quiescent state of stem cells, their labeling processes face
a substantial challenge.327 Bright yellow uorescent GQDs328
showed direct and easy uptake into stem cells without affecting
their viability, proliferation or differentiation capacity. This was
the rst use of stabilizer-free graphene as a uorescent label in
long-term stem cell imaging. Three different types of stem cells,
namely neurosphere cells (NSCs), pancreatic progenitor cells
(PPCs), and cardiac progenitor cells (CPCs) were incubated with
GQDs at a concentration of 25 mg mL1 for 24 h at 37 C. The
confocal uorescent images showed that the GQDs were local-
ized in the cytoplasm of the stem cells. The methyl thiazo-
lyldiphenyl tetrazolium bromide (MTT) assay veried the low
cytotoxicity of GQDs for stem cell imaging. In another study, the
uptake mechanism and biocompatibility of GQDs interacting
with human neural stem cells (hNSCs) were examined.329 TEM
images proved that the GQDs were internalized into hNSCs via
an endocytosis mechanism and were localized in the cytoplasm.
The researchers reported that GQDs did not inuence the self-
renewal capacity of hNSCs. Single cells separated from GQD-
labeled hNSCs still formed large neurospheres, and the cells

































































































View Article Onlinewere detected in the viability, proliferation, metabolic activity or
differentiation potential of NSCs aer treatment with GQDs.
Aer 14 days of differentiation, no differences were discovered
in the hNSC proliferation rate between the control group and
the 25 mg mL1 GQDs treatment group. The cells from both
groups exhibited an elongated cell morphology with neurite
outgrowth, resulting in the formation of an interconnected
neuronal network. Expression of glial brillary acidic protein
(GFAP) and neuron-specic class III beta-tubulin (Tuj1) showed
that the hNSCs could differentiate into glial cells and neurons,
respectively. In addition to the bio-imaging of stem cells, other
studies of GQD-based imaging have focused on tumor cells.
Numerous studies have conrmed that uorescent GQDs are
taken up by tumor cells. In 2014, Yang et al. reported the use of
B-GQDs for the imaging of HeLa cells.330 Zhu et al. cultured
human osteosarcoma (MG-63) cells with solvothermally fabri-
cated GQDs, which showed two-color imaging using different
excitation wavelengths.331 Peng et al. incubated green lumines-
cent GQDs with the T47D human breast cancer cell line and
stained their nucleus with DAPI.332 The images included a phase
contrast, where the nuclei were stained blue with DAPI, and
high contrast green uorescent GQDs were observed in the
perinuclear region in the triple over-layered images.
Dong et al.333 incubated MCF-7 human breast cancer cells
with GQDs synthesized via acidic oxidation, and a bright green
emission could be detected using confocal laser scanning
microscopy with excitation at 488 nm. The section analysis of
single MCF-7 cells showed that GQDs not only labeled the cell
membrane and the cytoplasm, but also the nucleus. This was
the rst time that luminescent carbon nanomaterials were
shown to tag the cell nucleus. Moreover, Hela cells,334 A-549
cells,335 macrophages and hepatocellular cells335 have all been
labeled with uorescent GQDs by different groups. All these
studies reported the low cytotoxicity and biocompatibility of
GQDs using the MTT assay, and hence they could be used for
bio-imaging. Fluorescent GQDs functionalized with folic acid
(FA) were introduced as highly selective and specic tumor cell
imaging agents by Wang et al.336 The uorescence of the GQDs
in FA over-expressing HeLa cells was noticeably stronger than in
A549 and HEK293A cells, which both express the FA receptor
(FR) at low levels.
7.4.2. In vivo imaging. CQDs have also been used by several
groups for in vivo imaging in living animals.337–339 Due to their
low toxicity, CQDs are a better choice for in vivo imaging than
heavy metal-containing QDs. CQDs that are obtained from
diverse carbon sources and are functionalized with suitable
functional groups are capable of emission under excitation in
both the UV and NIR regions of the electromagnetic spectrum.
For in vivo optical imaging, it is better to use longer wavelengths
since the photon penetration in tissue is higher and the back-
ground auto-uorescence is lower. Although the uorescence
emission of CQDs is oen weaker at longer wavelengths,
imaging at these wavelengths is better to reduce the tissue auto-
uorescence background and leads to higher signal-to-noise
ratios overall. For example, CQDs synthesized via the oxi-
dization of carbon nanotubes with a size of 3–4 nm were used
for in vivo imaging in mice. Aer excitation with blue, green,2278 | RSC Adv., 2021, 11, 2253–2291yellow, orange, red, deep red and NIR light and segregating the
green background auto-uorescence, clear spots were observed
in the uorescence images with red or longer excitation wave-
lengths. In comparison to the images captured with blue and
green excitation, excitation at 595 nm and higher showed the
best signal-to-background ratio.340
CQDs have some advantages compared to other commer-
cially available QDs for bio-imaging due to their high absorp-
tion coefficients. The higher absorptivity of CQDs can
compensate for their lower uorescence yield compared to
heavy metal QDs. In one study, PEG surface-passivated CQDs
were compared with CdSe/ZnS QDs. The PEG CQDs had better
absorptivity and they also protected the dots for in vivo bio-
imaging.305
The NIR emission of CQDs that were functionalized with
a hyper branched polymer increased compared to the CQDs
coated with a linear polymer (PEG). In vivo experiments in
a mouse model led to visualization of lymph nodes due to the
uorescent emission of the CQDs.341 CQDs can also be doped
with inorganic salts (e.g. ZnS) to increase their uorescence
yield for in vivo imaging. Injection of CQDs doped with ZnS
(CQDs–ZnS) into mice (compared to the non-doped CQDs)
showed a brighter emission. Green uorescent CQD–ZnS was
injected intradermally into the footpad and then transported
along the leg via the lymphatic vessels. The migration of CQD–
ZnS was slow in comparison to conventional semiconductor
QDs. One reason was that the size of the CQDs–ZnS was smaller,
while another reason could be due to the PEG functionalization.
These two properties would result in decreased interactions
with lymphatic cells.342
GQDs can also be exploited for in vivo imaging. Passivated
nanographene sheet particles with attached PEG (NGS-PEG)
with an average size of 30 nm were prepared by Yang et al.
and administered into mice aer tagging with the commonly
used NIR uorescent dye Cy7. In vivo uorescence imaging
showed the high tumor uptake of the NGS in several tumor
xenogra mouse models.343 The effectiveness of GQDs fabri-
cated via the one-step pyrolysis of L-glutamic acid was investi-
gated for in vivo imaging in mice by Wu et al.344 Aer injecting
the GQDs intradermally into the back of nude mice and intra-
muscularly into their right back leg, uorescence images of the
mice using different excitation and emission lters were
captured. The detectable uorescence from the intramuscular
injection site in the leg was higher with longer excitation and
emission wavelengths because of the better tissue penetration
of light. Ge et al. examined in vivo uorescence imaging using
red uorescent GQDs prepared via a hydrothermal method and
modied with polythiophene derivatives.345 Aer injection of
the GQD aqueous solution into the back of a nude mouse,
uorescent spots were observed against the background signal
of the mouse skin. The uorescent spots remained visible up to
1 week aer injection.7.5. Phototherapy
Surgery, radiotherapy and chemotherapy are the most common

































































































View Article Onlineexhibit undesirable side effects on other healthy tissues of the
body. Therefore, many novel treatment methods have been
developed to reduce the side effects of cancer therapy.346 In
recent years, several methods based on the therapeutic use of
light, such as photothermal therapy (PTT) and photodynamic
therapy (PDT), have attracted attention for the treatment of
cancer. PPT relies on the generation of heat from light
absorption, while PDT is based on the photochemical genera-
tion of reactive oxygen species to destroy tumors.346,347
Phototherapy is one of the independent therapeutic func-
tions of GQDs and CQDs in synergism with light irradiation.
The therapeutic function of phototherapy is based on the
formation of lesions and causing damage to tissues. Accord-
ingly, for more efficient function, besides the sonosensitizing
properties of the material, targeting abilities are required for
specialized therapy and reducing side effects, which can be
provided by GQDs and CQDs due to their physiochemical
properties.346
7.5.1. Mechanism of PDT. Photodynamic therapy is
a promising method for the treatment of human diseases,
including several disorders of the skin, infections, and also
cancer. PDT involves the application of a photosensitizer (PS) or
a photoactive dye, and a particular wavelength of light tailored
to the PS absorption spectrum (Fig. 18). PDT is considered non-
invasive, selective and can be combined with other therapies.348
When PSs are exposed to a specic wavelength of light, they can
generate a reactive form of molecular oxygen (singlet oxygen,
1O2) with the ability to kill surrounding cells. This technique
can be used solely or in combination with surgery, chemo-
therapy and ionizing radiation.349 Various PSs such as porphy-
rins and phthalocyanines have been shown to carry out
simultaneous cancer imaging and tumor destruction, and some
of these PSs have been approved for clinical applications.350 PDT
is used in the treatment of different cancers such as skin cancer,
liver tumors, esophageal cancer and malignant gliomas.351–353Fig. 18 Schematic illustration of phototherapy methods based on organ
filled with other photosensitizers. Excitation of O-dots and their subseque
© 2021 The Author(s). Published by the Royal Society of ChemistryThe PDT procedure consists of 3 important elements, PS, light,
and ambient oxygen. PSs absorb energy from light, and then the
oxygen molecules turn into singlet oxygen and other reactive
oxygen species, which induce rapid cytotoxicity, causing
apoptosis and necrosis.354 PSs are classied in two groups, i.e.
porphyrins including other tetra pyrrole derivatives, and non-
porphyrins.350
7.5.2. Mechanism of PTT. Photothermal therapy is based
on the absorption of photons by a chromophore, which
produces heat from optical energy to kill cancer cells.355 NIR
lasers are oen used for PTT in order to target the tumor either
directly or interstitially through an optical ber. This energy is
turned into heat through optical absorption followed by non-
radiative relaxation of the excited state. Consequently, selec-
tive photothermal absorbing materials or chromophores can be
used in the treatment of advanced tumors with little damage to
surrounding healthy tissues. The aim of PTT is to uniformly
increase the temperature within the tumor up to 41 C or
higher. Liao et al. recently claimed that 41 C can initiate the
degradation of tumor cells.3567.6. O-dots in phototherapy
The properties of O-dots include their chemical inertness, high
water solubility, photostability, interplay between optoelec-
tronic features and shape/size, uorescence resonance energy
transfer, high stability under physiological conditions, specic
accumulation at target sites, facile surface functionalization,
and high absorption coefficient due to their sp2 hybridized C–C
bonds. Thus, these features make them an attractive chromo-
phore for phototherapy.345,357,358
One problem with many clinically employed PSs is that they
are not specically targeted to tumors, and consequently
spatially controlled irradiation is utilized to target the site of
treatment. Moreover, PS administration can cause ROS
production in healthy cells, meaning that care needs to be takenic dots. O-dots can act as photosensitizers or they can be coated or
nt loss of energy to lower energy states lead to the generation of ROS.

































































































View Article Onlineaer phototherapies to prevent light exposure to lessen the risk
of skin photosensitivity.345 The QY of 1O2 production from NPs
and quantum dots (QDs) alone are not as high as that from
molecular PSs; however, O-dots can be applied as antennae to
improve light harvesting and energy transfer to molecular PS
owing to their high (size dependent345) light absorption cross-
section.359 Furthermore, broad-wavelength excitable O-dots with
tunable up-conversion and down-conversion properties can also
be applied in PDT.360
The large number of mobile p-electrons in O-dots leads to
comparatively strong electron–electron scattering and weak
electron–electron interactions. It was predicted that the p-
electrons in O-dots can act in a similar manner to the free
electrons in metallic nano-clusters rather than that in inorganic
semiconductor QDs. The limited QY of O-dots means that most
of the absorbed light will be ultimately transformed into heat
through several non-radiative relaxation pathways. This
consideration suggests their potential use in PTT rather than
PDT.361,362
7.6.1. O-dots in PDT. The concept of utilizing O-dots for
cancer therapy dates back to 2015, when Liu et al. reported the
synthesis of CQDs with high QYs as labeling agents for cells.
The CQDs developed by Liu et al. exhibited signicant disper-
sion and excellent optical properties such as high uorescence
and photostability, resistance to photobleaching, and facile
coupling with biological species. They also reported that these
structures can play a substantial role in PDT.363 In another
study, Huang et al. reported that CQDs could be utilized as
carriers for the PS drug Ce6, as well as the ability of these
structures to generate ROS.364 As reported in their study, the
ROS could be produced by the uorescence resonance energy
transfer phenomenon (FRET) from CQDs to Ce6. Zheng et al.
doped CQDs with carbon nitride (C3N4), producing an increase
in infrared absorption.365 They employed a polymer consisting
of protoporphyrin and a tumor-targeting sequence for the
functionalization of carbon nitride-doped CQDs. Zheng and his
group used this approach to overcome tumor hypoxia and
improve PDT, which is oen not very effective in hypoxic
tumors. Water splitting occurred, producing oxygen and
hydrogen in vivo using irradiation from a 639 nm laser. The
extra oxygen formed increased the yield of 1O2 to improve PDT.
Carbon dots attached to a platinum-coordinated porphyrin
formed a composite (CQDs@PtPor) through the electrostatic
interaction between four platinated porphyrins and the nega-
tively charged CQDs in a complex (PtPor). This was utilized as
a theranostic agent for PDT cancer therapy.366 They claimed that
the composite combined the optical properties of CQDs and the
anticancer activity of porphyrin into a distinctive new structure.
Pheophytin is a type of Mg-free chlorophyll derivative and is
also a natural product with low toxicity, which was used as a raw
carbon source for the synthesis of CQDs with the assistance of
a microwave method byWeng and co-workers. The hydrophobic
CQDs exhibited high potential to emit NIR light, with an exci-
tation peak at around 680 nm, and high 1O2 production with
a quantum yield of 0.62. The self-assembled CQDs from the
precursor (DSPE-mPEG2000) showed efficient 1O2 generation.
This carbon dot assembly was found to be useful as2280 | RSC Adv., 2021, 11, 2253–2291a uorescence imaging agent and also as a smart PDT agent.
Thus, these nanostructures can serve as a new phototheranostic
agent for cancer therapy.367
Meng and co-workers reported the synthesis of a novel
multifunctional two-photon excited nano probe based on
GQDs, GQD@MnO2, with the capability for imaging glutathione
(GSH) in biological systems and for improved PDT. GSH is
a ubiquitous tri-peptide and the most common intracellular
thiol, which has been reported to consume 1O2. Thus, GSH can
decrease the effectiveness of PDT, as conrmed in vitro by Meng
et al. Their prepared nanoprobe exhibited high sensitivity and
selectivity toward GSH because the reduction of MnO2 nano-
sheets could be carried out by intracellular GSH, which led to its
overall consumption. Therefore, GSH removal could improve
the efficacy of PDT by GQDs. Researchers reported that the PDT
efficiency of the prepared nanoprobes was better than that of
GQDs alone by incubating HeLa cells with GQDs or
GQD@MnO2 and irradiating with 560 nm light for 30 min. In
addition, they found that nitrogen-doped GQDs had a good two-
photon absorption cross-section for enhanced PDT. Doping
GQDs with N can cause widening the light adsorption peak and
prolongation of the PL lifetime. NGQDs also exhibited a good
PTT effect when compared with other doped materials.
Recently, Wen et al. conrmed this hypothesis.367,368
The combination of GQDs and methylene blue (MB) to
destroy pathogenic bacteria by enhancing light-mediated 1O2
generation was reported by Monroe and co-workers. Moreover,
their group also measured the ability of GQDS, MB and other
GQD-MB combinations to kill MCF-7 breast cancer cells. They
utilized the cell counting method to evaluate the cytotoxicity of
GQDs, MB and a 1 : 1 GQD : MB mixture. The measurement of
1O2 generation in the medium was then checked by means of
singlet oxygen sensor, in which the dye 20,70-dichlorodihydro-
uorescein diacetate (H2DCFDA) was used to measure the
production of reactive oxygen species. Another dye, H2DCFDA,
was used to examine the total ROS generated during the
process. Monroe and co-workers conrmed that GQDs and MB
could be taken up into MCF-7 cells, and the most appropriate
proportion for the combination was found to be 1 : 1, which led
to superior cytotoxicity and the highest amount of 1O2 and ROS.
In general, they found that the effects on MCF-7 cells were not
dependent on the GQD concentration or the intensity of light.369
7.6.2. O-dots in PTT. Bao et al. used co-doped CQDs with
sulfur and nitrogen as in vivo theranostic agents in mouse
models.370 They obtained high photon conversion efficiencies
(>59%), which were useful for photoluminescence and photo-
acoustic imaging. The dominant mechanism for the destruc-
tion of the tumor involved the accumulation of CQDs around
the cancer cells via passive targeting with no active targeting
species. A high photothermal conversion, good optical and
photoacoustic performance, and renal excretion were observed
for the co-doped CQDs. Nitrogen and oxygen co-doped CQDs
(N–O-CQDs) with strong absorbance in the NIR region were
prepared via a one-stepmolecular fusion route from the starting
materials 1,3,6-trinitropyrene (TNP) and N-containing polymer
branched polyethylene imine (BPEI) by Geng et al., as shown in
Fig. 19. The black N–O-CQDs exhibited good photostability and© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 19 (a) Confocal laser-scanning microscopy (CLSM) images of HeLa cells incubated with N–O-CDs (100 mg mL1) excited by 405 nm. (b). In
vivo fluorescence imaging of the tumor site from amouse intratumor injectedwith N–O-CDs at 0 h, 5min, 1 h, and 3 h post-treatment. The color
bars represent the fluorescence intensity. Red circles indicate the position of the implanted tumor. (c) Synthetic procedure of N–O-CQDs (this
figure has been reproduced from ref. 371 with permission from Elsevier, Copyright 2018).
Fig. 20 (a and d) Schematic illustration of the ZIF-8/GQD nano-
particles with encapsulation of Dox molecules and synergistic Dox
delivery and photo thermal therapy.373 (b and d) Dox-CuS@GQDs
nanoparticles and their therapeutic function.375 (c and d) Schematic
illustration of drug loading and release from mesoporous silica

































































































View Article Onlinebiocompatibility, and could function not only as a new uo-
rescence imaging agent but also an excellent PTT agent in vivo.
Moreover, the structure possessed good optical properties, bio-
imaging ability, photothermal effects, and therapeutic efficacy
in vivo. The low power density used (0.8 W cm2) and high PTT
conversion efficiency (h¼ 38.3%) were claimed as advantages of
N–O-CQDs. Geng et al. claimed that this structure can act as
a theranostic agent for uorescence imaging and PTT both in
vitro and in vivo (Fig. 19a and b).371
In another study, Thakut and co-workers developed highly
crystalline GQDs with good physicochemical and NIR optical
properties via the carbonization of Ficus racemosa leaves, which
is a cluster g tree native to India.372 The production yield of
GQDs was 18% with a QY of about 14.16%. The synthesized
GQDs exhibited good compatibility and photostability in both
organic and aqueous media. The potential of these GQDs to act
as in vivo uorescent probes was conrmed via a cytotoxicity
analysis. The generation of ROS in a concentration-dependent
manner combined with PTT activity was observed aer excita-
tion with 808 nm laser. The GQDs were stable for 30 min under
continuous laser irradiation. These highly uorescent GQDs
were also used for PTT of MDA-MB-231 breast cancer cells.
Tian and co-workers synthesized a composite derived from
metal–organic frameworks combined with GQDs. They used
zeolitic imidazolate framework-8 (ZIF-8) as a drug nanocarrier
plus embedded GQDs as the PTT chromophore. The drug
release performance, PTT efficacy and synergistic therapeutic
efficacy were systematically investigated using Dox as a model
anticancer drug. The Dox-loaded ZIF-8/GQD nanoparticles
could transform NIR irradiation into heat. Using 4T1 breast
cancer cells as a model, they showed the synergistic effect of the
combined chemotherapy and PTT compared with either
chemotherapy or PTT used alone (Fig. 20a).373
Liu and co-workers reported the fabrication of GQDs with
strong absorption at 1070 nm in the NIR-II region. They used

































































































View Article Onlineprecursor. Their synthesis was controlled by the decomposition
of hydrogen peroxide under a highmagnetic eld (9 T). Uniform
size (3.6 nm), tunable quantum yield (16.67%), and high PTT
conversion efficiency (33.45%) were the most important
advantages reported by Liu and co-workers.374
Zheng et al. investigated a multifunctional platform
composed of GQDs modied with hollow copper sulde nano-
particles (CuSNPs) for controlled intracellular drug release and
enhanced PTT-chemotherapy. Initially, the CuSNPs were
synthesized and used as an encapsulating agent for Dox.
Subsequently, GQDs were decorated on the surface of the
CuSNPs. The benecial properties of the nanoplatform include
its good crystal structure, constant nanoscale size, colloidal
stability, high drug encapsulation ability, and improved optical
absorbance. Drug release could be triggered by high tempera-
ture and/or NIR laser irradiation. Confocal images and ow
cytometry showed a signicant level of NIR-triggered Dox
release inside MDA-MB-231 cells. The combination of PTT and
chemotherapy by Zheng et al. is illustrated in Fig. 20b.375
The synthesis of mesoporous silica nanoparticles (MSNs)
capped with GQDs was reported by Gao and colleagues as
a novel PTT and redox-responsive drug delivery system. An
amidation reaction between cysteine and amino-functionalized
MSNs was used to create disulde bonds and Rhodamine B
(RhB), a red uorescent dye, was then incorporated into the
mesoporous structure of MSNs as a model drug. Capping MSNs
with GQDs acted as a blocking agent on the pores of meso-
porous structure in order to control the release of the RhB
cargo. The prepared nanocomposite demonstrated redox
responsiveness to the presence of glutathione (GSH), which
cleaved the disulde bonds and released the loaded drug under
redox control (Fig. 20c).376
7.6.3. Combined therapies. As mentioned before, biolog-
ical systems are complex, and thus interfering with them in
order to overcome a disease requires multifunctional
approaches. Moreover, some diseases do not respond to mono-
therapies properly. In this case, combined therapies are
a possible solution. GQDs and CQDs are suitable structures that
can possess independent therapeutic functions besides drug
delivery applications. Moreover, they can become stimuli
responsive with some modications. These properties make
them promising candidates for combined therapy. Synergism of
chemotherapy and photodynamic therapy is an example of this
approach.
In this section, we summarize the recent reports of O-dot-
based nanocomposites that have combined imaging with one
or more other modalities, including phototherapy, chemo-
therapy, and computed tomography (CT) (Fig. 21).
Lan et al. synthesized CQDs with an absorption of up to
1100 nm via the hydrothermal treatment of 1,3,6-trinitropyrene
and Na2SO3.377 The CQDs could simultaneously provide strong
uorescence and generate 1O2 through a two-photon excitation
mechanism. An outstanding PTT conversion ability under
800 nm femtosecond pulsed laser irradiation was also observed.
The wide absorption peak of the CQDs enabled them to be used
as a photoacoustic (PA) imaging probe. In vitro and in vivo
experiments showed that the uorescent CQDs had good2282 | RSC Adv., 2021, 11, 2253–2291biocompatibility and they could be used as a versatile photo-
theranostic probe for PA/uorescence imaging, and as a PDT/
PTT dual photoactive material with synergistic effects for
killing cancer cells using a single NIR laser.377
Zhang and co-workers synthesized magneto-uorescent
Fe3O4/CQDs coated with single-walled carbon nanotubes
(SWNTs) as a multifunctional theranostic material for targeted
imaging plus chemo/photodynamic/photothermal triple-mode
therapy. In this study, Dox as a model chemotherapy drug,
was encapsulated in the porous structure of the SWCNTs-PEG-
Fe3O4@CQD nanocarriers with high efficiency. These magneto-
uorescent structures were then conjugated to the sgc8c DNA
aptamer, which specically recognizes the receptor tyrosine-
protein kinase-like 7 (also known as colon carcinoma kinase
4, CCK4) for targeted dual mode uorescence/magnetic reso-
nance (MR) imaging. The multifunctional porous structure
demonstrated the synergistic killing of lung cancer cells via
PDT, PTT and rapid release of Dox under simultaneous NIR
laser irradiation and low pH.
In another study, Wo and co-workers synthesized GQD-
coated hollow magnetic nanospheres (HMNSs) as a versatile
system with a synergistic combination of magneto-mechanical,
photothermal, photodynamic and chemotherapy of cancer.
These mixed modalities structurally and physically destroyed
cancer cells, where their morphology was visibly different from
the cells killed by other therapies. HMNSs were coated with
silica shells and linked to carboxylated GQDs in a core–shell
structure. The synthesized composite was then loaded with Dox
and stabilized with liposomes. The system was able to destroy
cancer cells using four different therapeutic modalities in
a synergistic manner including magnetic eld-mediated
mechanical stimulation, PTT damage, PDT toxicity, and
chemotherapy.378
Xuan and colleagues functionalized the surface of GQDs
with gold nanosphere clusters. They performed this process via
a simple procedure, in which the reduction and stabilization of
gold were both carried out by the GQDs themselves. They
showed good dispersion, stability, excellent performance for
photoacoustic imaging (PAI) and computed tomography (CT)
imaging, low cytotoxicity, and PTT conversion efficiency of up to
51.31%. Cellular and animal experiments showed that the tar-
geted PAI/CT imaging of tumors could be enhanced by modi-
cation with folic acid (FA). The combination chemo-PTT
therapy could be carried out through controlled Dox release
from GQD under the inuence of heat and the acidic environ-
ment of the tumor. Furthermore, the observed therapeutic
effect was superior compared to all the single modes alone.
Body weight monitoring, hematoxylin and eosin (H&E)
staining of organs, and blood biochemical indicators demon-
strated the good safety and low toxicity of the probe aer
injection.379
Badrigilan et al. synthesized nanoparticles from super
paramagnetic iron oxide (SPIO) and bismuth oxide (Bi2O3) and
they coated them with GQDs for use as in vitro CT/MR dual-
modal biomedical imaging probes and for cancer-specic
PTT. These nanocomposites showed strong light absorbance
with a wide-band in the NIR region. The photo-thermal© 2021 The Author(s). Published by the Royal Society of Chemistry

































































































View Article Onlineconversion efficacy (h) was 31.8%, with high photostability
upon irradiation with 808 nm laser. The results of in vitro PTT of
cancer cells showed a dose-dependent loss of viability of
53.4% in comparison to the laser alone group (3.0%). The
presence of Bi with a high atomic number (Z ¼ 83) had good X-
ray attenuation capability (175%) and strong shortening of the
T2-relaxation time.3808. Conclusions and future
perspectives
In this review, we summarized the recent progress in the
design, properties, and theranostic applications of O-dots
including graphene quantum dots and carbon quantum dots
and introduce this new concept in order to facilitate new
possibilities in the synthesis, preparation and application of
these materials. These small-sized quantum dots have attrac-
ted much attention in theranostics due to their exceptional
optical and chemical properties such as non-blinking, low-
toxicity and photostability. They are now being investigated
in medical diagnostics and imaging, bio-sensing, drug/gene
delivery, photoactivation, and light-activated therapy. Here,
we highlight some future directions that can produce further
advances in this eld.
One of the reasons for the interest in O-dots is that their
synthetic process is relatively simple, and their integration with
other nanomaterials is easy. Despite the wide variety of
approaches and precursors that have been employed for their
fabrication, none of these nanostructures have been transi-
tioned into a marketable product to date. Better controlled
synthetic approaches, more precise characterization, and more
extensive nanotoxicology studies will be required for effective
translation. Because the uorescence properties and the
quantum yield are related to the overall composition and the
presence of chemical groups on the surface of O-dots, stan-
dardization of the preparation procedures is urgently required.© 2021 The Author(s). Published by the Royal Society of ChemistrySurface engineering is used to further functionalize O-dots
by tailoring their surface coating with reactive groups for
subsequent chemical modication. The reactive groups on the
surface of O-dots can be reacted with the terminal groups of
organic, polymeric, inorganic and biological materials via
covalent bonds, electrostatic interactions and hydrogen bonds.
Unfortunately, precisely controlled surface passivation has been
challenging to date. The number of reactive groups capping the
surface and the ratio of reactive groups on modifying molecules
are difficult to be exactly controlled. In the future, scientists
should continue to develop rational strategies for the prepara-
tion of O-dots with bright uorescence emission in the red/
near-IR spectral regions to allow deeper optical imaging in
tissue and decrease the interference from background auto-
uorescence. Therefore, efficient one-pot procedures for
producing surface-passivated O-dots with high quantum yields
need further attention.
O-dots can act as carriers for many pharmaceutical applica-
tions. Once functionalized with various polymers, they can serve
as versatile biocompatible gene delivery vehicles. Moreover,
they can be designed to have extended therapeutic lifetimes
within the body. Despite some safety concerns about O-dots,
many studies have reported their use in hybrid forms for bio-
logical applications, particularly in gene delivery. Hybridization
approaches using biocompatible polymers have been tested in
order to lower their potential toxicity and to increase their
biocompatibility and applicability as multi-functional imaging
probes and delivery vehicles. However, more systematic toxi-
cology studies are needed to conrm the safety and understand
the pharmacokinetics of O-dots.
Multifunctional combinational therapeutic applications,
including PPT, PDT, photoacoustic therapy, MRI, chemo-
therapy, and computed tomography can increase therapeutic
efficacy, overcome tumor resistance, and eradicate undesirable
side effects. However, the practical applications of O-dots that
rely on their optical properties, size and shape, surface chem-

































































































View Article Onlineapplications. The ability to combine a number of imaging and
therapeutic modalities within a single platform may still allow
theranostics to become a reality in the coming years.
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57 S. Campuzano, P. Yáñez-Sedeño and J. M. Pingarrón,
Nanomaterials, 2019, DOI: 10.3390/nano9040634.
58 M. J. Molaei, RSC Adv., 2019, 9, 6460–6481.
59 K. Nekoueian, M. Amiri, M. Sillanpää, F. Marken,
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M. Krysmann and E. P. Giannelis, Chem. Mater., 2011, 24,
6–8.
179 X. Liu, N. Zhang, T. Bing and D. Shangguan, Anal. Chem.,
2014, 86, 2289–2296.
180 W. Kong, H. Wu, Z. Ye, R. Li, T. Xu and B. Zhang, J. Lumin.,
2014, 148, 238–242.
181 A. Quaranta, S. Carturan, A. Campagnaro, M. Dalla Palma,
M. Giarola, N. Daldosso, G. Maggioni and G. Mariotto, Thin
Solid Films, 2014, 553, 188–192.
182 A. Gupta and C. K. Nandi, Sens. Actuators, B, 2017, 245, 137–
145.
183 Z. Su, H. Shen, H. Wang, J. Wang, J. Li, G. U. Nienhaus,
L. Shang and G. Wei, Adv. Funct. Mater., 2015, 25, 5472–
5478.
184 F. Chiti and C. M. Dobson, Annu. Rev. Biochem., 2006, 75,
DOI: 10.1146/annurev.biochem.75.101304.123901.
185 M. Li, S. E. Howson, K. Dong, N. Gao, J. Ren, P. Scott and
X. Qu, J. Am. Chem. Soc., 2014, 136, 11655–11663.
186 C. Glabe, Neurobiol. Aging, 2006, 27, 570–575.
187 X. Han, J. Park, W. Wu, A. Malagon, L. Wang, E. Vargas,
A. Wikramanayake, K. N. Houk and R. Leblanc, Chem.
Sci., 2017, 8, 2003–2009.
188 Y. Song, P. N. Cheng, L. Zhu, E. G. Moore and J. S. Moore, J.
Am. Chem. Soc., 2014, 136, 5233–5236.
189 S. Palmal, N. R. Jana and N. R. Jana, J. Phys. Chem. C, 2014,
118, 21630–21638.
190 J. A. Yang, B. J. Johnson, S. Wu, W. S. Woods, J. M. George
and C. J. Murphy, Langmuir, 2013, 29, 4603–4615.
191 C. Cabaleiro-Lago, F. Quinlan-Pluck, I. Lynch, S. Lindman,
A. M. Minogue, E. Thulin, D. M. Walsh, K. A. Dawson and
S. Linse, J. Am. Chem. Soc., 2008, 130, 15437–15443.
192 C. Li and R. Mezzenga, Nanoscale, 2013, 5, 6207–6218.
193 S. Li, L. Wang, C. C. Chusuei, V. M. Suarez,
P. L. Blackwelder, M. Micic, J. Orbulescu and
R. M. Leblanc, Chem. Mater., 2015, 27, 1764–1771.
194 S. Li, Z. Peng and R. M. Leblanc, Anal. Chem., 2015, 87,
6455–6459.
195 C. Frieden, Protein Sci., 2007, 16, 2334–2344.
196 S. Zhu, T. Lu, G. Zhang, J. Xu, Y. Song, Y. Li, L. Wang,
B. Yang and F. Li, J. Mater. Chem. B, 2016, 4, 4913–4921.
197 S. Radic, T. Davis, P. Ke and F. Ding, RSC Adv., 2015, 5,
105489–105498.
198 M. Yousaf, H. Huang, P. Li, C. Wang and Y. Yang, ACS
Chem. Neurosci., 2017, 8, 1368–1377.
199 G. Rusciano, A. De Luca, G. Pesce and A. Sasso, Carbon,
2009, 47, 2950–2957.
200 S. Nandi, R. Malishev, K. P. Kootery, S. Kolusheva and
R. Jelinek, Chem. Commun., 2014, 50, 10299–10302.
201 S. Nandi, R. Malishev, S. K. Bhunia, S. Kolusheva, J. Jopp
and R. Jelinek, Biophys. J., 2016, 110, 2016–2025.
202 S. Nandi, M. Ritenberg and R. Jelinek, Analyst, 2015, 140,
4232–4237.
203 T. K. Mandal and N. Parvin, J. Biomed. Nanotechnol., 2011,

































































































View Article Online204 S. K. Misra, I. Srivastava, I. Tripathi, E. Daza,
F. Ostadhossein and D. Pan, J. Am. Chem. Soc., 2017, 139,
1746–1749.
205 M. J. Meziani, X. Dong, L. Zhu, L. P. Jones, G. E. LeCroy,
F. Yang, S. Wang, P. Wang, Y. Zhao and L. Yang, ACS
Appl. Mater. Interfaces, 2016, 8, 10761–10766.
206 W. Bing, H. Sun, Z. Yan, J. Ren and X. Qu, Small, 2016, 12,
4713–4718.
207 N. Zhou, S. Zhu, S. Maharjan, Z. Hao, Y. Song, X. Zhao,
Y. Jiang, B. Yang and L. Lu, RSC Adv., 2014, 4, 62086–62095.
208 T.Wang, S. Zhu and X. Jiang, Toxicol. Res., 2015, 4, 885–894.
209 A. H. Loo, Z. Sofer, D. Bouša, P. Ulbrich, A. Bonanni and
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F. Pariente, R. Wannemacher, K. Weber, J. Popp and
E. Lorenzo, Sens. Actuators, B, 2018, 256, 226–233.
249 W. Zhang, L. Shi, Y. Liu, X. Meng, H. Xu, Y. Xu, B. Liu,
X. Fang, H.-B. Li and T. Ding, RSC Adv., 2017, 7, 20345–
20353.
250 N. Gao, W. Yang, H. Nie, Y. Gong, J. Jing, L. Gao and
X. Zhang, Biosens. Bioelectron., 2017, 96, 300–307.
251 D. Lei, W. Yang, Y. Gong, J. Jing, H. Nie, B. Yu and X. Zhang,
Sens. Actuators, B, 2016, 230, 714–720.
252 J. Zhang, X. Zhao, M. Xian, C. Dong and S. Shuang, Talanta,

































































































View Article Online253 A. Zhao, Z. Chen, C. Zhao, N. Gao, J. Ren and X. Qu, Carbon,
2015, 85, 309–327.
254 M. X. Gao, L. Yang, Y. Zheng, X. X. Yang, H. Y. Zou, J. Han,
Z. X. Liu, Y. F. Li and C. Z. Huang, Chem.–Eur. J., 2017, 23,
2171–2178.
255 H. Motaghi, M. A. Mehrgardi and P. Bouvet, Sci. Rep., 2017,
7, 10513.
256 D. Musumeci, C. Platella, C. Riccardi, F. Moccia and
D. Montesarchio, Cancer, 2017, 9, 174.
257 L. Yang, Z. Wang, J. Wang, W. Jiang, X. Jiang, Z. Bai, Y. He,
J. Jiang, D. Wang and L. Yang, Nanoscale, 2016, 8, 6801–
6809.
258 J. Pardo, Z. Peng and R. M. Leblanc, Molecules, 2018, 23,
378.
259 T. Feng, X. Ai, H. Ong and Y. Zhao, ACS Appl. Mater.
Interfaces, 2016, 8, 18732–18740.
260 X.-W. Hua, Y.-W. Bao, H.-Y. Wang, Z. Chen and F.-G. Wu,
Nanoscale, 2017, 9, 2150–2161.
261 J. S. Sidhu, A. Singh, N. Garg, N. Kaur and N. Singh, Analyst,
2018, 143, 1853–1861.
262 S. Wang, C. Li, M. Qian, H. Jiang, W. Shi, J. Chen,
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